Author: "Scheid C" / Database: OpenAIRE - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Scheid C"' showing total 45 results

Start Over Author "Scheid C" Database OpenAIRE

45 results on '"Scheid C"'

1. Long-lasting remissions in high-risk AML and MDS following sequential therapy with chemotherapy, reduced-intensity conditioning for allogeneic transplantation, and prophylactic DLT

Author: Schmid, Christoph, Schleuning, M., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., Scheid, C., Holtick, U., Keil, F., Sandherr, M., and Kolb, H.
Published: 2022

2. Respiratory viruses dynamics and interactions: ten years of surveillance in central Europe

Author: Horemheb-Rubio, G., Eggeling, R., Schmeiβer, N., Pfeifer, N., Lengauer, T., Gärtner, B., Prifert, C., Kochanek, M., Scheid, C., Adams, O., Kaiser, R., Weissbrich, B., Berger, A., Palupsky, K., Huzly, D., Tiemann, C., Borena, W., Lindauer, A., Liebert, U., Siemens, H., Hofmann, J., Eis-Hübinger, A., Grundmann, H., Kehlen, A., Oehme, A., Schnitzler, P., Kühn, J., Heim, A., Sauerbrei, A., Schmidt, B., Beck, R., Hoffmann, D., Michel, D., Nitschko, H., Aepinus, C., Dreier, J., Puchhammer-Stoeckl, E., Kaup, T., Redlberger, M., Kessler, H., Obermeier, M., Weise, K., Bartsch, P., Devide, A., Niesters, B., Kleines, M., Krumbholz, A., Meyer, T., Gohl, P., Schüttler, C., Gorgievski, M., Pagarolas, A., Gulich, W., Ziegler, T., Wintsche, B., Griego, M., Bossart, W., and Respiratory Virus Network
Subjects: Rhinovirus, Coinfection, Virus Diseases, Viruses, Public Health, Environmental and Occupational Health, Humans, Infant, Respiratory Tract Infections
Abstract: Background Lower respiratory tract infections are among the main causes of death. Although there are many respiratory viruses, diagnostic efforts are focused mainly on influenza. The Respiratory Viruses Network (RespVir) collects infection data, primarily from German university hospitals, for a high diversity of infections by respiratory pathogens. In this study, we computationally analysed a subset of the RespVir database, covering 217,150 samples tested for 17 different viral pathogens in the time span from 2010 to 2019. Methods We calculated the prevalence of 17 respiratory viruses, analysed their seasonality patterns using information-theoretic measures and agglomerative clustering, and analysed their propensity for dual infection using a new metric dubbed average coinfection exclusion score (ACES). Results After initial data pre-processing, we retained 206,814 samples, corresponding to 1,408,657 performed tests. We found that Influenza viruses were reported for almost the half of all infections and that they exhibited the highest degree of seasonality. Coinfections of viruses are frequent; the most prevalent coinfection was rhinovirus/bocavirus and most of the virus pairs had a positive ACES indicating a tendency to exclude each other regarding infection. Conclusions The analysis of respiratory viruses dynamics in monoinfection and coinfection contributes to the prevention, diagnostic, treatment, and development of new therapeutics. Data obtained from multiplex testing is fundamental for this analysis and should be prioritized over single pathogen testing.
Published: 2022
Full Text: View/download PDF

3. Phase I trial of MB-CART2019.1 in patientes with relapsed or refratory B-cell non-Hodgkin lymphoma: 2 year follow-up report [Poster]

Author: Borchmann, P., Lohneis, A., Gödel, P., Balke-Want, H., Schmid, Christoph, Ayuk, F., Holtkamp, S., Hanssens, L., Zadoyan, G., Friedrichs, B., Assenmacher, M., Bürger, I., Schneider, D., Overstijns, T., Scheid, C., Holtick, U., Miltenyi, S., and Hallek, M.
Subjects: ddc:610
Published: 2022

4. Results from the phase-Ib/II combination trial MPNSG-0212 : Ruxolitinib plus pomalidomide in myelofibrosis with anemia

Author: Stegelmann, F., Koschmieder, S., Heidel, F., Hochhaus, A., Hebart, H., Isfort, S., Reiter, A., Bangerter, M., Waller, C., Wolleschak, D., Scheid, C., Göthert, Joachim, Schafhausen, P., Kindler, T., Radsak, M. P., Gattermann, N., Möhle, R., von Bubnoff, N., Brümmendorf, T. H., Döhner, H., Griesshammer, M., and Döhner, K.
Subjects: Medizin, ComputingMethodologies_GENERAL
Abstract: Poster-Abstract
Published: 2021

5. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

Author: Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele, von Weikersthal, L. Fischer, Hahn, M., Schlimok, G., Reichert, D., Janssen, J., Martens, U., Majunke, P., Reichert, Peter, Neben, K., Korsten, S., Scholz, Ch, Oldenkott, B., Heßling, J., Kingreen, D., Sperling, C., Schelenz, C., Blau, I., Urmersbach, A., Ludwig, W., Le Coutre, P., Arnold, R., de Wit, M., Pezzutto, A., Schäfer, E., Schroers, R., Lochter, A., Behringer, D., Ko, Y., Weidenhöfer, S., Verbeek, W., Brossart, P., Trenn, G., Pommerien, W., Krauter, J., Doering, G., Munzinger, H., Diekmann, C., Hertenstein, B., Stier, S., Möller-Faßbender, F., Hänel, M., Zöller, T., Lamberti, C., Koch, B., Henzel, A., Wagner, S., Schmalenbach, A., Hoffknecht, M., Ehninger, G., Kiani, A., Illmer, T., Aul, C., Flaßhove, M., Henneke, F., Simon, M., Müller, L., Becker, H., Janz, R., Eckart, M. J., Fuchs, R., Schlegel, F., Wattad, M., Rudolph, R., Beelen, D. W., Lindemann, A., Linck, D., Wassman, Jäger, E., Al-Batran, S., Reiber, T., Waller, C. F., Hoeffkes, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Pralle, H., Runde, V., Hoyer, A., Tessen, H., Trümper, L., Schmidt, C., Sieber, M., Eschenburg, H., Depenbusch, R., Rösel, S., Lindemann, H. W., Wolf, H., Spohn, C., Moeller, R., Hossfeld, D., Zander, A., Schafhausen, P., Köster, H., Hollburg, W., Schmitz, N., Dürk, H., Hemeier, M., Grote-Metke, A., Weischer, H., Bechtel, B., Balleisen, L., Sosada, M., Ho, A., Petersen, V., Dengler, J., Bildat, S., Hahn, L., Dietzfelbinger, H., Gröschel, W., Bartholomäus, A., Freier, W., Sievers, B., Pfreundschuh, I. M., Herrmann, T., Fauser, A., Menzel, J., Kemmerling, M., Hansen, R., Link, H., Schatz, M., Bentz, M., Prümmer, O., Kneba, M., Heymanns, J., Schmitz, S., Scheid, C., Lollert, A., Neise, M., Planker, M., Stauch, M., Schröder, M., Kempf, B., Vehling-Kaiser, U., Kremers, S., Köchling, G., Hartmann, F., Neuhaus, T., Fetscher, S., Kämpfe, D., Heil, G., Uppenkamp, M., Goldmann, B., Huber, T. Fischer, Hieber, U., Plöger, C., Griesshammer, M., Lange, C., Göttler, B., Lunscken, C., Schiel, X., Scheidegger, C., Stötzer, O., Hitz, H., Schick, H., Völkl, S., Spiekermann, K., Berdel, W., Hebart, H., Ladda, E., Schmidt, P., Burkhardt, U., Hentschke, S., Falge, C., Reschke, D., Köhne, C. A., Müller-Naendrup, C., Sauer, M., Frühauf, S., Ranft, K., Dencausse, Y., Sandritter, B., Baake, G., Hofknecht, M., Dengler, R., Edinger, M., Schenk, M., Wehmeier, A., Weidelich, H. P., Pihusch, R., Stahlhut, K., Baldus, M., Matzdorff, A., Geer, T., Schanz, S., Käfer, G., Gassmann, W., Priebe-Richter, C., Demandt, M., Springer, G., Fiechtner, H., Denzlinger, C., Schleicher, J., Assman, D., Gaeckler, R., Adam, G., Waladkhani, A., Rendenbach, B., Forstbauer, H., Kanz, L., Jacki, S., Stegelmann, F., Kalhori, N., Nusch, A., Langer, W., Müller, F., Brettner, S., Uebelmesser, B., Kamp, T., Schadeck-Gressel, C., Josten, K., Klein, O., Schwerdtfeger, R., Baurmann, H., Strotkötter, H., Fett, W., Raghavachar, A., Maintz, C., Goebler, M. C., Schlag, R., Elsel, W., Wernli, M., Heim, D., Wuillemin, W., Hess, U., Gmür, J., and Mayer, J.
Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Published: 2020
Full Text: View/download PDF

6. Transplantationsmedizin in der Intensivmedizin

Author: Michels, G., Ruhparwar, A., Pfister, R., Welte, T., Gottlieb, J., Andriopoulos, N., Teschner, S., Burst, V., Mertens, J., Stippel, D., Herter-Sprie, G., Shimabukuro-Vornhagen, A., Böll, B., von Bergwelt-Baildon, M., Theurich, S., Vehreschild, J., Scheid, C., Chemnitz, J., and Kochanek, M.
Subjects: Article
Abstract: Die Betreuung von Patienten vor und nach einer Organtransplantation gehört zum Gebiet der „speziellen Intensivmedizin“ des jeweiligen Fachbereichs. Die transplantationsspezifische Intensivmedizin setzt daher ein interdisziplinäres Management voraus. Neben der Organprotektion bzw. dem Monitoring von speziellen transplantationsrelevanten Problemen steht die Immunsuppression. Auf das Management mit Immunsuppressiva und von transplantationsassoziierten, intensivmedizinisch relevanten Problemen wird in diesem Kapitel eingegangen. Speziell werden Herz-, Lungen-, Leber-, Nieren- und Stammzelltransplantationen dargestellt.
Published: 2016

7. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author: Dimopoulos, M.A. Gay, F. Schjesvold, F. Beksac, M. Hajek, R. Weisel, K.C. Goldschmidt, H. Maisnar, V. Moreau, P. Min, C.K. Pluta, A. Chng, W.-J. Kaiser, M. Zweegman, S. Mateos, M.-V. Spencer, A. Iida, S. Morgan, G. Suryanarayan, K. Teng, Z. Skacel, T. Palumbo, A. Dash, A.B. Gupta, N. Labotka, R. Rajkumar, S.V. Bar, D. Basso, A. Fantl, D. He, S. Horvath, N. Lee, C. Rowlings, P. Taylor, K. Cochrane, T. Kwok, F. Ramanathan, S. Agis, H. Zojer, N. Kentos, A. Offner, F. Van Droogenbroeck, J. Wu, K.L. Maiolino, A. Martinez, G. Zanella, K. Capra, M. Araújo, S. Gregora, E. Pour, L. Scudla, V. Spicka, I. Abildgaard, N. Andersen, N. Jensen, B.A. Helleberg, C. Plesner, T. Salomo, M. Svirskaite, A. Delarue, R. Blau, I. Schieferdecker, A. Teleanu, V. Munder, M. Röllig, C. Salwender, H.-J. Fuhrmann, S. Weisel, K. Duerig, J. Zeis, M. Klein, S. Reimer, P. Schmidt, C. Scheid, C. Mayer, K. Hoffmann, M. Sosada, M. Dimopoulos, A. Delimpasi, S. Kyrtsonis, M.-C. Anagnostopoulos, A. Nagy, Z. Illés, Á. Egyed, M. Borbényi, Z. Mikala, G. Dally, N. Horowitz, N. Gutwein, O. Nemets, A. Vaxman, I. Shvetz, O. Trestman, S. Ruchlemer, R. Nagler, A. Tadmor, T. Rouvio, O. Preis, M. Cavo, M. De Rosa, L. Musto, P. Cafro, A. Tosi, P. Offidani, M. Corso, A. Rossi, G. Liberati, A.M. Bosi, A. Suzuki, K. Nakaseko, C. Ishikawa, T. Matsumoto, M. Nagai, H. Sunami, K. Chou, T. Akashi, K. Takezako, N. Hagiwara, S. Eom, H.S. Jo, D.-Y. Kim, J.S. Lee, J.H. Yoon, S.S. Yoon, D.H. Kim, K. Levin, M.-D. Vellenga, E. Minnema, M. Waage, A. Haukås, E. Grosicki, S. Pluta, A. Robak, T. Marques, H. Bergantim, R. Campilho, F. Chng, W.J. Goh, Y.T. McDonald, A. Rapoport, B. Álvarez Rivas, M.A. De Arriba de La Fuente, F. González Montes, Y. Martin Sanchez, J. Mateos, M.V. Oriol Rocafiguera, A. Rosinol, L. San Miguel, J. Pérez de Oteyza, J. Encinas, C. Alegre-Amor, A. López-Guía, A. Axelsson, P. Carlson, K. Stromberg, O. Hansson, M. Hveding Blimark, C. Mueller, R. Chen, C.-C. Liu, T.-C. Huang, S.-Y. Wang, P.-N. Na Nakorn, T. Prayongratana, K. Unal, A. Goker, H. Sonmez, M. Korenkova, S. Chaidos, A. Oakervee, H. Sati, H. Benjamin, R. Wechalekar, A. Garg, M. Ramasamy, K. Cook, G. Chantry, A. Jenner, M. Buadi, F. Berryman, R. Janakiram, M. TOURMALINE-MM3 study group
Abstract: Background: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. Methods: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m2) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1–4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. Findings: Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3–35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7–33·8] vs 21·3 months [18·0–24·7]; hazard ratio 0·72, 95% CI 0·58–0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. Interpretation: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma. Funding: Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company. © 2019 Elsevier Ltd
Published: 2019

8. An upscaled DGTD method for time-domain electromagnetics

Author: Gobé, A, Lanteri, S., Léger, Raphaël, Scheid, C, Valentin, F., Numerical modeling and high performance computing for evolution problems in complex domains and heterogeneous media (NACHOS), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Jean Alexandre Dieudonné (JAD), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Jean Alexandre Dieudonné (JAD), Laboratorio Nacional de Computação Cientifica [Rio de Janeiro] (LNCC / MCT), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Jean Alexandre Dieudonné (LJAD), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), and Laboratoire Jean Alexandre Dieudonné (LJAD)
Subjects: [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation
Abstract: International audience; In this work, we address time-dependent electromagnetic wave propagation problems with strong multiscale features with application to nanophotonics, where problems usually involve complex mul-tiscale geometries, heterogeneous materials, and intense, localized electromagnetic fields. Nanopho-tonics simulations require very fine meshes to incorporate the influence of geometries as well as high order polynomial interpolations to minimize dispersion. Our goal is to design a family of innovative high performance numerical methods perfectly adapted for the simulation of such multiscale problems. For that purpose we extend the Multiscale Hybrid-Mixed (MHM) finite element method, originally proposed for the Laplace problem in [1], to the solution of 2d and 3d transient Maxwell equations with heterogeneous media. The MHM method arises from the decomposition of the exact electromagnetic fields in terms of the solutions of locally independent Maxwell problems. Those problems are tied together with an one field formulation on top of a coarse mesh skeleton. The multiscale basis functions, which are responsible for upscaling, are also driven by local Maxwell problems. A high order Discontinuous Galerkin method (see [2]) in space combined with a second-order explicit leapfrog scheme in time discretizes the local problems. This makes the MHM method effective and parallelizable, and yields a staggered algorithm within a divide-and-conquer framework. In this talk we will present the general formulation of this MHM-DGTD method and presen some preliminary numerical results in 2d. REFERENCES 1. C. Harder, D. Paredes, and F. Valentin. A family of Multiscale Hybrid-Mixed finite element methods for the Darcy equation with rough coefficients. J. Comput. Phys., 245:107-130, 2013. 2. S. Descombes, C. Durochat, S. Lanteri, L. Moya, C. Scheid, and J. Viquerat. Recent advances on a DGTD method for time-domain electromagnetics. Photonics and Nanostructures-Fundamentals and Applications, 11(4):291-302, 2013.
Published: 2018

9. High order curvilinear DGTD methods for local and nonlocal plasmonics

Author: Schmitt, N, Viquerat, J, Lanteri, S., Scheid, C, Numerical modeling and high performance computing for evolution problems in complex domains and heterogeneous media (NACHOS), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Jean Alexandre Dieudonné (JAD), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Jean Alexandre Dieudonné (JAD), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Jean Alexandre Dieudonné (LJAD), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), and Laboratoire Jean Alexandre Dieudonné (LJAD)
Subjects: [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation
Abstract: International audience; The DGTD (Discontinuous Galerkin Time-Domain) method has emerged in nanophotonics in the recent years [1] as a complementary or alternative modeling approach for time-domain nanoscale light-matter interactions beside the widely used FDTD (Finite Difference Time-Domain) method. A DG method [2] can be seen as a classical Finite Element (FE) method for which the global continuity of the approximation is lifted. Similarly to a FE method, the physical unknowns are approximated on a finite set of basis functions. However, for DG, the support of basis functions are restrained to a single discretization cell. Hence, the solution produced by a DG method is discontinuous (similarly to finite volumes), and different field values are stored for each element interface degree of freedom. The three main consequences are that (i) a DG method naturally handles material and field discontinuities, (ii) the weak formulation is local to an element, implying no large mass matrix inversion in the solving process if an explicit time scheme is used, and (iii) the order of the polynomial approximation in space can be made arbitrarily high by adding more degrees of freedom inside the elements. The connection between cells is restored by the use of a numerical flux. The discontinuity of the approximation makes room for numerous methodological improvements, such as efficient parallelization or the use of non-conforming and hybrid meshes A DG method os also very flexible with regards to time integration, motivating the design of local time stepping as well as locally implicit strategies. In the quest of higher accuracy and lower time to solution, a tailored treatment of the approximation of curvilinear geometrical features [3] is worth considering, especially in the presence of nanogaps or when assessing imperfect design of nanostructures. The use of very coarse discretization meshes leveraging tetrahedral curvilinear elements for the simulation of three-dimensional nanoscale light-matter interactions is assessed in this study, which is conducted in the framework of high order DGTD methods for solving the system of Maxwell equations coupled to a generalized model of local dispersion effects [3], as well as to a (linearized) hydrodynamic Drude model [4] for dealing with nonlocal dispersion effects [5]. REFERENCES 1. K. Busch, M. König, and J. Niegemann. Discontinuous Galerkin methods in nanophotonics. DGTD method for the numerical modeling of the interaction of light with nanometer scale metallic structures taking into account non-local dispersion effects. J. Comput. Phys., 316:396-415, 2016. 5. A. Moreau, C. Cirac`Cirac`ı, and D.R. Smith. The impact of nonlocal response on metallo-dielectric multilayers and optical patch antennas. Phys. Rev. B, pages 1-12, 2012.
Published: 2018

10. Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma : Final results of the GMMG-PERSPECTIVE trial

Author: Weisel, K., Salwender, H., Scheid, C., Zago, M., Besemer, B., Hänel, M., Dürig, Jan, Munder, M., Lindemann, H.-W., Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Kanz, L., Goldschmidt, H., and GMMG
Subjects: Medizin
Published: 2018

11. Allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete remission (CR) in patients with acute myeloid leukemia (AML) : Results from the AMLCG1999 trial

Author: Evers, G., Beelen, Dietrich W., Braess, J., Sauerland, Maria Cristina, Kolb, H. J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Krug, U., Müller-Tidow, C., Schliemann, C., Mikesch, J.-H., Lenz, G., Wörmann, B. J., Hiddemann, W., Berdel, W. E., and Stelljes, M.
Subjects: Medizin
Published: 2018

12. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Author: Auner, H, Iacobelli, S, Sbianchi, G, Knol-Bout, C, Blaise, D, Russell, N, Apperley, J, Pohlreich, D, Browne, P, Kobbe, G, Isaksson, C, Lenhoff, S, Scheid, C, Touzeau, C, Jantunen, E, Anagnostopoulos, A, Yakoub-Agha, I, Tanase, A, Schaap, N, Wiktor-Jedrzejczak, W, Krejci, M, Schönland, S, Morris, C, Garderet, L, and Kröger, N
Subjects: Adult, Male, Transplantation Conditioning, Immunology, Transplantation, Autologous, 1102 Cardiovascular Medicine And Haematology, Article, Plasma Cell Disorders, Settore MED/01 - Statistica Medica, Recurrence, immune system diseases, hemic and lymphatic diseases, Humans, cardiovascular diseases, neoplasms, Melphalan, Aged, Dose-Response Relationship, Drug, Hematopoietic Stem Cell Transplantation, Middle Aged, Survival Analysis, Treatment Outcome, surgical procedures, operative, Female, Multiple Myeloma, Stem Cell Transplantation
Abstract: Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m2 and melphalan 140 mg/m2 are equally effective and tolerable in clinically relevant patient subgroups we analyzed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, hematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 mg/m2 (n=245) and melphalan 200 mg/m2 (n=1719) groups. Multivariable subgroup analysis showed that disease status at transplantation interacted with overall survival, progression-free survival, and cumulative incidence of relapse, with a significant advantage associated with melphalan 200 mg/m2 in patients transplanted in less than partial response (adjusted hazard ratios for melphalan 200 mg/m2 versus melphalan 140 mg/m2: 0.5, 0.54, and 0.56). In contrast, transplantation in very good partial or complete response significantly favored melphalan 140 mg/m2 for overall survival (adjusted hazard ratio: 2.02). Age, renal function, prior proteasome inhibitor treatment, gender, or Karnofsky score did not interact with overall/progression-free survival or relapse rate in the melphalan dose groups. There were no significant survival or relapse rate differences between melphalan 200 mg/m2 and melphalan 140 mg/m2 patients with high-risk or standard-risk chromosomal abnormalities. In conclusion, remission status at the time of transplantation may favor the use of melphalan 200 mg/m2 or melphalan 140 mg/m2 for key transplant outcomes (NCT01362972).
Published: 2017

13. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author: Hehlmann, R., Lauseker, M., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Saußele, S., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Pfirrmann, M., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Krause, S., Berdel, W. E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, Roland, Wernli, M., Kolb, H. J., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Neubauer, A., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A., Hasford, J., Hossfeld, D. K., SAKK and the German CML Study Group, Nerl, C., and Gratwohl, A.
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, Cancer Research, Medizin, Alpha interferon, 610 Medicine & health, 03 medical and health sciences, 0302 clinical medicine, chronic myeloid leukemia, Internal medicine, medicine, Survival analysis, Relative survival, business.industry, Myeloid leukemia, Imatinib, Hematology, medicine.disease, 3. Good health, Surgery, Leukemia, 030104 developmental biology, Imatinib mesylate, 030220 oncology & carcinogenesis, Cytarabine, Original Article, business, medicine.drug
Abstract: Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival. peerReviewed
Published: 2017
Full Text: View/download PDF

14. No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties

Author: Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Porras, R.P., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroger, N., and Schetelig, J.
Published: 2017

15. Multiscale hybrid methods for time-domain electromagnetics

Author: Lanteri, S, Léger, R, Paredes, D, Scheid, C, Valentin, F, Numerical modeling and high performance computing for evolution problems in complex domains and heterogeneous media (NACHOS), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Jean Alexandre Dieudonné (JAD), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Pontificia Universidad Católica de Valparaíso (PUCV), Laboratoire Jean Alexandre Dieudonné (JAD), Laboratorio Nacional de Computação Cientifica [Rio de Janeiro] (LNCC / MCT), HOSCAR CNPq-Inria project, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Jean Alexandre Dieudonné (LJAD), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), and Laboratoire Jean Alexandre Dieudonné (LJAD)
Subjects: Digital computer simulation, Finite element method, Computational electromagnetics, [SPI.ELEC]Engineering Sciences [physics]/Electromagnetism, Multiscale FE method, Matemàtiques i estadística::Anàlisi numèrica::Mètodes en elements finits [Àrees temàtiques de la UPC], Simulació per ordinador digital, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, [MATH.MATH-NA]Mathematics [math]/Numerical Analysis [math.NA]
Abstract: International audience; In this work, we are interested in the propagation of electromagnetic waves in complex media. More precisely, we would like to study time dependent wave propagation problems with strong multiscale features (possibly in space and time). In this context we would like to contribute in the design of innovative numerical methods particularly well suited to the simulation of such problems. Indeed when a PDE model is approximated via classical finite element type method, it may suffer from a loss of accuracy when the solution presents multiscale features on coarse meshes. To address this issue, we rely on the concept of multiscale basis functions that is one solution to allow for accuracy even on coarse meshes. These basis functions are defined via algebraic relations. Contrary to classical polynomial approximation, they render by themselves a part of the high-contrast features of the problem at hand. Recently, a new family of finite element methods has been introduced in [1]-[2], referred as " Multiscale Hybrid-Mixed methods " (MHM), which is well adapted to the simulation of high-contrast or heterogeneous problems. The underlying approach relies on a two level discretization. Shortly, basis functions computed on a fine (second level) mesh allow for the reconstruction of the solution on a coarse (first level) mesh. Such MHM have been initially designed in the context of stationary problems, such as Darcy flows. In this work, we propose to extend the concept of MHM to time dependent electromagnetic wave propagation problems. The model problem relies on the time dependent Maxwell's equations. The continuity of the electric field is relaxed via the introduction of a Lagrange multiplier. The solutions are expressed on a basis computed at the second level that incorporates the heterogeneity of the problem via the resolution of a PDE. Several schemes are proposed from implicit to explicit time schemes and continuous finite elements to discontinuous ones for the spatial discretization of the local problems at the second level.
Published: 2015

16. Allogeneic stem cell transplantation for MDS patients more than 70 years of age. A report of MDS subcommittee of CMWP of EBMT

Author: Heidenreich, S., Zabelina, T., Biezen, A. van, Finke, J., Platzbecker, U., Niederwieser, D., Einsele, H., Bethge, W., Schwerdtfeger, R., Beelen, D., Tischer, J., Nagler, A., Zachee, P., Scheid, C., Witte, T. de, Robin, M., and Kroger, N.
Published: 2015

17. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Author: Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson Ansah A, Legros L, Harousseau JL, Rigal Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde Dahl T, Hjorth Hansen H, Jedrzejczak W, Dmoszynska A, Starzak Dwozdz J, Holowiecki J, Kyrcz Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent D.J., PANE, FABRIZIO, Saglio, G, Kim, Dw, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, Re, Hochhaus, A, Hughes, Tp, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, Ra, Kantarjian, Hm, Moiraghi, B, Perez, M, Greil, R, Valent, P, Bosly, A, Martiat, P, Noens, L, André, M, Verhoef, G, Conchon, M, Souza, C, Nonino, A, Hungria, V, Zanichelli, Ma, Colturato, V, Forrest, D, Lipton, Jh, Savoie, Ml, Delage, R, Lalancette, M, Quintero, G, Gomez, M, Klamova, H, Faber, E, Bjerrum, Ow, Fredriksen, H, Vestergaard, H, Marcher, C, Kamel, H, Elzawam, H, Porkka, K, Remes, K, Reiffers, J, Guilhot, F, Facon, T, Tulliez, M, Guerci Bresler, Ap, Nicolini, Fe, Charbonnier, A, Rea, D, Johnson Ansah, A, Legros, L, Harousseau, Jl, Rigal Huguet, F, Escoffre, M, Gardembas, M, Guyotat, D, Cahn, Jy, Gattermann, N, Ottmann, O, Niederwieser, D, Stegelmann, F, Schafhausen, P, Brümmendorf, T, Duyster, J, Blumenstengel, K, Scheid, C, Kneba, M, Kwong, Yl, Masszi, T, Petrini, M, Alimena, G, Di Raimondo, F, Rosti, G, Rotoli, B, Pane, Fabrizio, Pungolino, E, Amadori, S, Abruzzese, E, Fioritoni, G, Lauria, F, Bosi, A, Martelli, M, Rambaldi, A, Ferrara, F, Nobile, F, Gobbi, M, Carella, Am, Orlandi, Em, Leoni, P, Tiribelli, M, Levis, A, Imamura, M, Takahashi, N, Tsukamoto, N, Chiba, S, Nagai, T, Okamoto, S, Miura, O, Kurokawa, M, Ohnishi, K, Toba, K, Nakao, S, Tomita, A, Miyamura, K, Hino, M, Maeda, Y, Kimura, A, Kawaguchi, T, Miyazaki, Y, Nakaseko, C, Jinnai, I, Matsuda, A, Matsumura, I, Ishikawa, J, Ohyashiki, K, Okada, M, Usuki, K, Kobayashi, Y, Ohishi, K, Imai, K, Miyawaki, S, Kanda, Y, Park, Sy, Kim, Hj, Sohn, Sk, Lee, Kh, Jung, Cw, Ong, Tc, Gómez Almaguer, D, Kassack, J, Ossenkoppele, Gj, Gedde Dahl, T, Hjorth Hansen, H, Jedrzejczak, W, Dmoszynska, A, Starzak Dwozdz, J, Holowiecki, J, Kyrcz Krzemieñ, S, Kuliczkowski, K, Zaritsky, A, Turkina, A, Pospelova, T, Goh, Yt, Koh, Lp, Demitrovicova, L, Mistrik, M, Ruff, P, Louw, V, Dreosti, Lm, Novitzky, N, Cohen, G, Cervantes, F, Cañizo, C, de Paz, R, del Castillo, S, Perez Encinas, M, Sanz Alonso, M, Marin, F, Pérez López, R, Hernandez Boluda, J, Echeveste Gutierrez, Ma, Odriozola, J, Herrera, P, Steegman, Jl, Conde, E, Lopez, P, Giraldo, P, Boque, C, Heredia, B, Font, Aj, Rodriguez, Rf, Rodriguez, Mj, Batlle, J, Stenke, L, Lehmann, S, Wadenvik, H, Simonsson, B, Markevärn, B, Själander, A, Richter, J, Bjoreman, M, Eriksson, Km, Chalandon, Y, Shih, Ly, Yao, M, Wang, Mc, Jootar, S, Bunworasate, U, Ulkü, B, Haznedar, R, Undar, B, Sahin, B, Marin, D, Smith, G, Byrne, J, Holyoake, T, Kalaycio, M, Akard, L, Heaney, M, Al Janadi, A, Goldberg, S, Powell, B, Harker, Wg, Shea, T, Gingrich, R, Glass, J, Paquette, R, Siegrist, C, Woodson, M, Fehrenbacher, L, Koh, H, Flinn, I, Arrowsmith, E, Ervin, T, Guerra, M, Wallach, H, Berry, W, Burke, J, Edenfield, W, Guzley, G, Davis, J, Richards, D, Schlossman, D, Kolibaba, K, Alemany, C, Savin, M, Robbins, G, Lopez, J, Goldman, Jm, Camm, J, Schiffer, Ca, and Sargent, D. J.
Published: 2010

18. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

Author: Haaß, Wiltrud, Kleiner, Helga, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Morgner, A., Herbst, R., Matek, W., Lamberti, C., Zöller, T., Koch, B., Marth, T., Henzel, A., Wagner, S., Woska, E., German CML Study Group, Neumann, F., Hoffknecht, M. M., Illmer, T., Wolf, T., Ehninger, G., Kiani, A., Platzbecker, U., Aul, C., Badrakhan, C. D., Giagounidis, A., Wernli, M., Flaßhove, M., Henneke, F., Moritz, T., Simon, M., Müller, L. L., Janz, R., Eckart, M., Häcker, B., Rech, D., Mackensen, A., Bargetzi, M., Krause, S. W., Staib, P., Schlegel, F., Wätzig, K., Rudolph, R., Wattad, M., Baur, F. K., Heit, W., Beelen, D. W., Hüttmann, A., Fischer von Weikersthal, L., Novotny, J., Trenschel, R., Lindemann, A., Linck, D., Jäger, E., Al-Batran, Salah-Eddin, Ottmann, O. G., Serve, H., Reiber, T., Semsek, D., Gro, V., Waller, C., Kühnemund, A., Hoeffkes, H. G., Lambertz, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Rummel, M. J., Burchardt, A., Pralle, H., Müller, S., Runde, V., Klei, M., Westheider, J., Hoyer, A., Tessen, H. W., Hesse, A., Trümper, L., Binder, C., Schmidt, C. A., Hirt, C., Hahn, M., Sieber, M., Eschenburg, H., Wilhelm, S., Depenbusch, R., Rösel, S., Eimermacher, H., Spohn, C., Moeller, R., Schmitz, N., Nickelsen, M., Schlimok, G., Engel, E., Haatanen, T., Hollburg, W., Platz, D., Köster, H., Bokemeyer, C., Schafhausen, P., Grote-Metke, A., Bechtel, B., Hemeier, M., Reichert, D., Sosada, M., Ganser, A., Schlegelberger, B., Ho, A. D., Rohlfing, S., Dengler, J., Petersen, V., Porowski, P., Hahn, L., Dietzfelbinger, H., Weiß, Christel, Janssen, J., Gröschel, W., Bartholomäus, A., Pfreundschuh, M., Kemmerling, M., Hansen, R., Reeb, M., Link, H., Mahlmann, S., Mezger, J., Schatz, M., Furkert, J., Schmier, M., Gatter, J., Neumann, S., Heymanns, J., Steinmetz, H. T., Schmitz, S., Scheid, C., Planker, M., Frieling, T., Lollert, A., Mandel, T., Neise, M., Schröder, M., Greif, D., Kempf, B., März, W., Kremers, S., Müller, L., Hartmann, F., Heil, G., Goldmann, B., Majunke, P. J., Heinkele, P., Gregor, M., Theobald, M., Fischer, T., Thomas, S., Hensel, M., Plöger, C., Schuster, D., Brust, J., Hieber, U., Paliege, R., Hehlmann, R., Neubauer, A., Burchert, A., Graeven, U., Lange, C., Schmidt, G., Völkl, S., Schmidt, B., Hitz, H., Spiekermann, K., Reichert, P., Hiddemann, W., Haferlach, T., Haferlach, C., Schnittger, S., Stötzer, O., Scheidegger, C., Fischer, C., Berdel, W. E., Koppele, A., Hebart, H., Fuss, H., Snaga, A., Schmidt, P., Hoffmann, R., Reschke, D., Zirpel, I., Sauer, M., Lenk, G., Theilmann, L., Sandritter, B., Neben, K., Schenk, M., Dengler, R., Herr, W., Krause, S., Braun, B., Günther, E., Wacker, A., Pihusch, R., Baldus, M., Matzdorff, A., Staiger, H. J., Pollmeier, G., Grimminger, W., Geer, T., Schanz, S., Jür, C., Gassmann, W., Seitz, K., Kaesberger, J., Mück, R., Heim, D., Illerhaus, G., Denzlinger, C., Fiechtner, H., Springer, G., Hoffmann, D., Jacki, S. H., Kanz, L., Bross-Bach, U., Döhner, H., Stegelmann, F., Haferlach, Claudia, Gratwohl, A., Kalhori, N., Langer, W., Nusch, A., Wei, J., Kamp, T., Schadeck-Gressel, C., Schwerdtfeger, R., Josten, K. M., Klein, O., Fett, W., Tichelli, A., Strotkötter, H., Maintz, C., Groschek, M., Schlag, R., Elsel, W., Schüler, F., Dölken, G., Lindemann, H. W., Wolf, H. H., Schmoll, H. J., Korsten, S., Braumann, D., Hoelzer, P., Kleeberg, U., Hossfeld, D., Lange, E., Schubert, J., Weischer, H., Dürk, H. A., Kirchner, H. H., Bu, E C., Henesser, D., Sievers, B., Freier, W., Kaiser, U., Peest, D., Römer, E., Hermann, T., Fauser, A., Valverde, M. L., Menzel, J., Kemper, J., le Coutre, P., Hochhaus, A., La Rosée, P., Bentz, M., Prümmer, O., Kneba, M., Strack, U., Schoch, R., Severin, K., Stauch, M., Arnold, R., Karbach, U., Vehling-Kaiser, U., Köchling, G., Wei, U., Middeke, H., Neuhaus, T., Martin, H., Fetscher, S., Schmielau, J., Kämpfe, D., Ludwig, W. D., Uppenkamp, M., Wei, B., Thum, P., Wuillemin, W., Hofmann, W. K., Griesshammer, M., Tischler, H. J., Becker, M., Hanfstein, B., Müller, M., Ratei, R., Saußele, S., Lunscken, C., Kolb, H. J., Lutz, L., Hentrich, M., Nerl, C., Wendtner, C., Ladda, E., Gnad, M., Teutsch, C., Suna, H., Schmidt, E., Koschmieder, S., Falge, C., Wandt, H., Wilhelm, M., Köhne, C. H., Schweiger, C., Müller-Naendrup, C., Frühauf, S., Ludwig, F., Ranft, K., Dencausse, Y., Baake, G., Ritter, P. R., Kloke, O., Göttler, B., Schick, H. D., Schlegelberger, Brigitte, Urmersbach, A., Weidenhöfer, S., Weidinger, P., Wacker, D., Wehmeyer, J., Kreuser, E. D., Schlenska-Lange, A., Edinger, R., Andreesen, R., Wehmeier, A., Stahlhut, K., Blau, I., Käfer, G., Cerny, T., Hess, U., Priebe-Richter, C., Stange-Budumlu, O., Demandt, M., Freunek, G., Heidemann, E., Schleicher, J., Mergenthaler, H. G., Ihle, H., Boewer, C., Zeller, C., Laubenstein, H. P., Rendenbach, B., Clemens, M., Waladkhani, A. R., Forstbauer, H., Müller, F., Brettner, S., Raghavachar, A., Sperling, C., Kunzmann, V., Goebeler, M. E., Gmür, J., Schelenz, C., Koschuth, A., Kingreen, D., Heßling, J., Derwahl, K. M., Oldenkott, B., Müller, Martin C., Englisch, H. J., Thiel, E., Burmeister, T., Notter, M., de Wit, M., Rothaug, W., Büschel, G., Beyer, J., Dahmen, E., Hehlmann, Rüdiger, Biaggi, C., Lämmle, B., Friess, D., Baerlocher, G., Oppliger Leibundgut, E., Tobler, A., Just, M., Schäfer, E., Behringer, D., Brandt, M., Hofmann, Wolf-Karsten, Schmiegel, W., Vaupel, H. A., Verbeek, W., Ko, Y. D., Sauerbruch, T., Hahn-Ast, C., Janzen, V., Schmidt-Wolf, Ingo G. H., Trenn, G., Fabarius, Alice, van der Linde, M., Pommerien, W., Fritz, L., Krauter, J., Lordick, F., Fritsch, G., Pflüger, K. H., Diekmann, C., Kullmer, J., Doering, G., Seifarth, Wolfgang, Munzinger, H., Hertenstein, B., Peyn, A., Mayer, J., Zácková, D., Kujickova, J., Stier, S., Wejda, B., Möller-Faßbender, F., and Hänel, M.
Subjects: Adult, Aged, 80 and over, Chromosome Aberrations, Adolescent, Fusion Proteins, bcr-abl, Antineoplastic Agents, Chromosome Breakage, Middle Aged, Clonal Evolution, Young Adult, hemic and lymphatic diseases, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Proteolysis, Imatinib Mesylate, Humans, Blast Crisis, Separase, Research Article, Aged
Abstract: PLoS ONE 10(6), e0129648 (2015). doi:10.1371/journal.pone.0129648, Published by PLoS, Lawrence, Kan.
Published: 2015
Full Text: View/download PDF

19. A 43-YEAR-OLD WOMAN WITH A TEMPORAL MASS

Author: Hrvoje Miletic, Lee Jy, Martina Deckert, Werner Stenzel, and Scheid C
Subjects: Pathology, medicine.medical_specialty, Myeloid, medicine.diagnostic_test, business.industry, General Neuroscience, Myelodysplastic syndromes, Myeloid leukemia, Physical examination, medicine.disease, Article, Pathology and Forensic Medicine, Breast cancer, Myeloproliferative Disorders, medicine.anatomical_structure, Parenchyma, Medicine, Neurology (clinical), Sarcoma, business
Abstract: A 43-year-old woman with a past medical history of breast cancer and an acute myeloid leukemia (AML) presented with headache over a 3-week period. The clinical examination was completely unremarkable. CT and MRI scans showed a contrast enhancing lesion in the left temporal lobe. Histopathologic examination revealed a malignant, hematopoietic tumor with high mitotic activity, areas of necrosis and diffuse infiltration of the brain parenchyma. Positive staining for Chloroacetateesterase and lysozyme of tumor cells identified its myeloid lineage. The diagnosis was granulocytic sarcoma (GS)/chloroma, a metastatic manifestation of AML. Granulocytic sarcoma (GS) most often occurs in patients with AML, myelodysplastic syndromes and myeloproliferative disorders, and can involve any organ. However intracerebral manifestation of GS is a rare event. In this case histopathological features and differential diagnoses of intracerebral GS are discussed.
Published: 2006
Full Text: View/download PDF

20. Méthodologie SIG pour l'analyse des risques d’inondation pluviale à Hambourg

Author: Scheid, C., Schmitt, T.G., Bischoff, G., Hüffmeyer, N., Krieger, K., Waldhoff, A., Günner, C., University of Kaiserslautern [Kaiserslautern], and Brelot, Elodie
Subjects: Flooding, [SDE.IE]Environmental Sciences/Environmental Engineering, Inondation, Diagnostic
Abstract: Colloque avec actes et comité de lecture. Internationale.; International audience
Published: 2013

21. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

Author: Auel, B., Goldschmidt, H., Geer, T., Moehler, T. M., Platzbecker, U., Naumann, R., Blau, I., Hanel, M., Knauf, W., Nuckel, H., Salwender, H. J., Scheid, C., Weisel, K., Gorschluter, M., Glasmacher, A., Schmidt-Wolf, IGH, and German Refractory Myeloma Study Gr
Subjects: Oncology, medicine.medical_specialty, Vincristine, Hematology, Cyclophosphamide, business.industry, Medizin, Vinorelbine, Surgery, Thalidomide, Refractory, Internal medicine, medicine, Idarubicin, Original Article, business, Dexamethasone, medicine.drug
Abstract: Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.
Published: 2012

22. Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment : subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma

Author: Scheid, C., Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Hielscher, T., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Hanel, M., Vellenga, E., Schubert, J., Blau, I. W., Jie, A., van de Velde, H., Peter, N., Schaafsma, M., Lindemann, W., Kersten, M., Dührsen, Ulrich, Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Schouten, H., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H., Goldschmidt, H., GMMG, and HOVON
Subjects: Medizin
Published: 2011

23. Bortezomib before and after high-dose chemotherapy improves the survival in patients with newly diagnosed multiple myeloma and renal insufficiency - a subgroup analysis of the prospective randomised GMMG HD4/HOVON 65 study

Author: Scheid, C., Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., Hielscher, T., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Hanel, M., Vellenga, E., Schubert, J., Blau, I. W., Jie, A., van de Velde, H., Peter, N., Schaafsma, M., Lindemann, W., Kersten, M. J., Dührsen, Ulrich, Delforge, M., Weisel, K., Croockewit, S., Martin, H., Wittebol, S., Schouten, H., van Marwijk-Kooy, M., Wijermans, P., Lokhorst, H. M., Goldschmidt, H., and GMMG HOVON
Subjects: Medizin
Published: 2011

24. Activity and tolerability of nilotinib: A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant

Author: Koren-Michowitz, M. Le Coutre, P. Duyster, J. Scheid, C. Panayiotidis, P. Prejzner, W. Rowe, J.M. Schwarz, M. Goldschmidt, N. Nagler, A.
Subjects: hemic and lymphatic diseases
Abstract: BACKGROUND: Nilotinib is active in imatinib-resistant and -intolerant chronic myeloid leukemia patients and was recently approved for these indications. METHODS: Data on the efficacy and safety of nilotinib treatment were collected from 2 phase 2 expanded access clinical trials with similar designs (CAMN107AIL01 and ENACT). RESULTS: Of 88 study patients (58 chronic, 11 accelerated, 19 blast crisis), the best responses to nilotinib were complete hematologic response (CHR) in 27%, partial cytogenetic response in 12%, complete cytogenetic response in 14%, and major molecular response in 19%. Patients achieving at least a CHR during imatinib therapy were more likely to respond to nilotinib, and failure to achieve at least a CHR on imatinib therapy was predictive of progression or lack of response to nilotinib (P = .0021). Responses were not statistically different in subgroup analysis, including that of imatinib intolerance compared with imatinib resistance, presence of ABL kinase domain mutations compared with absence of mutations, and previous treatment with another second-generation tyrosine kinase inhibitor compared no prior treatment. The overall survival and progression-free survival rates at 1 year were 83% and 48% for the entire cohort, 93% and 66% in chronic phase, and 64% and 19% in advanced phase. Adverse hematological events included thrombocytopenia (all events, 27%; grade 3-4, 13%) and leukopenia (all events, 18%; grade 3-4, 10%). The majority of the nonhematological events were mild, the most common being rash, infection, bone pain, headache, nausea, and vomiting. CONCLUSIONS: Nilotinib treatment is an efficient and safe therapy for imatinib-resistant or -intolerant patients. Prior response to imatinib therapy is a predictor for the response to nilotinib. © 2010 American Cancer Society.
Published: 2010

25. Oxalate-Induced Damage to Renal Tubular Cells

Author: Scheid, C. R., Koul, H. K., Kennington, L., Hill, W. A., Luber-Narod, J., Jonassen, J., Honeyman, T., and Menon, M.
Subjects: oxalate, free radicals, calcium oxalate stone disease, LLC-PK1 cells, Nephrotoxicity, Biology
Abstract: Our own studies and those of others have shown that the incidence of calcium oxalate stones and plaques is markedly increased by nephrotoxins. The possible role of oxalate as a nephrotoxin has not been fully appreciated. However, recent studies in experimental animals and in cultured cells support this possibility. The results of these studies led us to hypothesize that hyperoxaluria promotes stone formation in several ways: by providing a substrate for the formation of the most common form of renal stones, calcium oxalate stones, and by inducing damage to renal epithelial cells. Damaged cells in turn would produce an environment favorable for crystal retention and provide membranous debris that promotes crystal nucleation, aggregation and adherence. The present report summarizes evidence for oxalate nephrotoxicity and discusses the potential importance of oxalate toxicity in the pathogenesis of stone disease.
Published: 1995

26. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation

Author: Rueping, M. J. G. T., Mueller, C., Oliver Cornely, Abduljalil, K., Fuhr, U., Scheid, C., Hallek, M., and Kohl, V.

27. A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany

Author: Kron, F., Glossmann, J. P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K. -A, Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Michael Hallek, and Wolf, J.

28. Prophylactic oral calcium-phosphate rinse reduces the incidence and severity of mucositis after autologous stem cell transplantation with BEAM conditioning

Author: Scheid, C., Hoermann, V., Huebel, K., Holtick, U., Theurich, S., Shimabukuro-Vornhagen, A., Chakupurakal, G., Chemnitz, J., Bergwelt-Baildon, M., and Michael Hallek

29. The impact of melphalan dosage on outcomes of autologous haematopoietic cell transplantation for multiple myeloma: Results from the EBMT collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study

Author: Auner, H., Iacobelli, S., Bianchi, G., Knol-Bout, C., Blaise, D., Russell, N., Apperley, J., Pohlreich, D., Browne, P., Kobbe, G., Isaksson, C., Lenhoff, S., Scheid, C., Chevallier, P., Jantunen, E., Anagnostopoulos, A., Yakoub-Agha, I., Tanase, A., Nicolaas Schaap, Wiktor-Jedrzejczak, W., Mayer, J., Schoenland, S., Morris, C., Garderet, L., and Kroeger, N.

30. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma

Author: Scheid, C., Pettengell, R., Ghielmini, M., John Radford, Morgenstern, G. R., Stern, P. L., and Crowther, D.

31. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

Author: Schäfer, E, Schlimok, G, Falge, C, Schmidt-Wolf, I, Schnittger, S, Staib, P, Kröger, N, Hochhaus, A, Scheid, C, Prümmer, O, Arnold, R, Haferlach, C, Spiekermann, K, Wehmeier, A, Th Fischer, J, Berger, U, Mayer, J, Kolb, H-J, Baerlocher, Gabriela M., Gratwohl, A, Reiter, A, Pfreundschuh, M, Hasford, J, Hertenstein, B, Schatz, M, Nerl, C, Bunjes, D, Fauser, A, Ho, A D, Beelen, D, Müller, M C, Rosselet, A, Wilhelm, M, Zander, A, Edinger, M, Hellmann, A, Sayer, H G, Goebeler, M-E, Hossfeld, D K, Novotny, J, Wulf, G, Büsche, G, Heimpel, H, Fabian, M, Pfirrmann, M, Baurmann, H, Ganser, A, Hehlmann, R, Aul, C, Schenk, M, Bormann, M, Schwerdtfeger, R, Kindler, T, Lindemann, H W, Döhner, H, Saußele, S, Schmitz, N, and Kuse, R
Subjects: hemic and lymphatic diseases, 610 Medicine & health, 3. Good health
Abstract: Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P

32. Novel highly potent CD4bs bNAb with restricted pathway to HIV-1 escape

Author: Schommers, P., Gruell, H., Abernathy, M. E., Dingens, A. S., Tran, M-K, Gristick, H. B., Barnes, C. O., Schoofs, T., Schlotz, M., Vanshylla, K., Kreer, C., Weiland, D., Holtick, U., Scheid, C., Valter, M. M., Gils, M. J., Sanders, R. W., Vehreschild, J. J., Oliver Cornely, Lehmann, C., Faetkenheuer, G., Seaman, M. S., Bloom, J. D., Bjorkman, P. J., and Klein, F.
Abstract: Purpose: Broadly HIV-1 neutralizing antibodies (bNAbs) can suppress viremia in humans and represent a novel approach for effective immunotherapy. However, bNAb monotherapy selects for antibody-resistant viral variants. Thus, we focused on the identification of new antibody combinations and/or novel bNAbs that restrict pathways of HIV-1 escape. Methods: We screened HIV-1 positive patients for their neutralizing capacities. Following, we performed single cell sorting and PCR of HIV-1 Env-reactive mature B cells of identified elite neutralizers. Found antibodies were tested for neutralization and binding capacities in vitro. Further, their antiviral activity was tested in an HIV-1 infected humanized mouse model. Results: Here we report the isolation of antibody 1–18, a VH1–46-encoded CD4 binding site (CD4bs) bNAb identified in an individual ranking among the top 1% neutralizers of 2,274 HIV-1-infected subjects. Tested on a 119-virus panel, 1–18 showed to be exceptionally broad and potent with a coverage of 97% and a mean IC50 of 0.048 lg/mL, exceeding the activity of most potent CD4bs bNAbs described to-date. A 2.4 Å cryo-EM structure of 1–18 bound to a native-like Env trimer revealed that it interacts with HIV-1 env similar to other CD4bs bNAbs, but includes additional contacts to the V3 loop of the adjacent protomer. Notably, in vitro, 1–18 maintained activity against viruses carrying mutations associated with escape from VRC01-class bNAbs. Further, its HIV-1 env wide escape profile differed critically from other CD4bs bNAbs. In humanized mice, monotherapy with 1–18 was sufficient to prevent the development of viral escape variants that rapidly emerged during treatment with other CD4bs bNAbs. Finally, 1–18 overcame classical HIV-1 mutations that are driven by VRC01-like bNAbs in vivo. Conclusion: 1–18 is a highly potent and broad bNAb that restricts escape and overcomes frequent CD4bs escape pathways, providing new options for bNAb combinations to prevent and treat HIV-1 infection.

33. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author: Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, Roland, Wernli, M., Schlegel, F., Schlag, R., De Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A., Hasford, J., and SAKK And The German CML Study Group
Subjects: 3. Good health
Abstract: Leukemia : normal and malignant hemopoiesis 31, 2398-2406 (2017). doi:10.1038/leu.2017.253, Published by Springer Nature, London

34. Non-myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia: A single institution experience

Author: Chakupurakal, G., Langerbeins, P., Leitzke, S., Schiller, J., Holtick, U., Theurich, S., James, R., Schneider, P., Michael Hallek, Bergwelt-Baildon, M., and Scheid, C.

35. Prediction of pressure losses in drilling fluid flows in circular and annular pipes and accessories

Author: Scheid, C. M., Calcada, L. A., Rocha, D. C., Pedro Aranha, Aragao, A. F. L., and Martins, A. L.

36. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author: Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, Gabriela M., Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, De Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, and Hasford, J
Subjects: 610 Medicine & health, 3. Good health
Abstract: Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

37. 412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis With Continuous Micafungin Compared to Posaconazole With Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A 6-Year Cohort Analysis

Author: Heimann S, Vehreschild M, Franke B, Cornely O, Hamprecht A, Piepenbrock E, Scheid C, and Jörg Janne Vehreschild

38. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous hematopoietic stem cell transplantation: A randomized trial

Author: Vehreschild, J. -J, Moritz, G., Vehreschild, M. J. G. T., Arenz, D., Mahne, M., Bredenfeld, H., Chemnitz, J., Klein, F., Cremer, B., Boell, B., Kaul, I., Wassmer, G., Michael Hallek, Scheid, C., and Cornely, O. A.

39. Designing fluid properties to minimize barite sag and its impact on annular pressure build up mitigation in producing offshore wells

Author: Calcada, L. A., Scheid, C. M., Da Cruz Meleiro, L. A., Bruno Oechsler, Fagundes, F. M., Santos, N. B. C., Oliveira Arouca, F., Damasceno, J. J. R., Souza, E., Waldmann, A. T., and Martins, A. L.

40. Unveiling the strong interaction among hadrons at the LHC

Author: Acharya, Shreyasi, Adamova, Dagmar, Ahn, Sang Un, Bhattacharjee, Buddhadeb, Yurchenko, Volodymyr, Zaccolo, Valentina, Zaman, Ali, Zampolli, Chiara, Correia Zanoli, Henrique Jose, Zardoshti, Nima, Zarochentsev, Andrey, Zavada, Petr, Zavyalov, Nikolay, Zbroszczyk, Hanna Paulina, Bianchi, Antonio, Zhalov, Mikhail, Zhang, Song, Zhang, Xiaoming, Zhang, Zuman, Zherebchevskii, Vladimir, Yu, Zhi, Zhou, Daicui, Zhou, You, Zhou, Zhuo, Zhu, Jianhui, Bianchi, Livio, Zhu, Ya, Zichichi, Antonino, Zinovjev, Gennady, Zurlo, Nicola, ALICE Collaboration, Bianchi, Nicola, Bielcik, Jaroslav, Bielcikova, Jana, Bilandzic, Ante, Biro, Gabor, Biswas, Rathijit, Biswas, Saikat, Akbar, Zaenal, Blair, Justin Thomas, Blau, Dmitry, Blume, Christoph, Boca, Gianluigi, Bock, Friederike, Bogdanov, Alexey, Boi, Stefano, Bok, Jeongsu, Boldizsar, Laszlo, Bolozdynya, Alexander, Akindinov, Alexander, Bombara, Marek, Bonomi, Germano, Borel, Herve, Borissov, Alexander, Bossi, Hannah, Botta, Elena, Bratrud, Lars, Braun-munzinger, Peter, Bregant, Marco, Broz, Michal, Al-turany, Mohammad, Bruna, Elena, Bruno, Giuseppe Eugenio, Buckland, Matthew Daniel, Budnikov, Dmitry, Buesching, Henner, Bufalino, Stefania, Bugnon, Ophelie, Buhler, Paul Alois, Buncic, Predrag, Buthelezi, Edith Zinhle, Alam, Sk Noor, Bashir Butt, Jamila, Bysiak, Sebastian Adam, Caffarri, Davide, Caliva, Alberto, Calvo Villar, Ernesto, Mejia Camacho, Juan Manuel, Soto Camacho, Rabi, Camerini, Paolo, De Moraes Canedo, Fabio, Capon, Aaron Allan, Silva De Albuquerque, Danilo, Carnesecchi, Francesca, Caron, Robin Albert Andre, Castillo Castellanos, Javier Ernesto, Castro, Andrew John, Casula, Ester Anna Rita, Catalano, Fabio, Ceballos Sanchez, Cesar, Chakraborty, Pritam, Chandra, Sinjini, Chang, Wan, Aleksandrov, Dmitry, Chapeland, Sylvain, Chartier, Marielle, Chattopadhyay, Subhasis, Chattopadhyay, Sukalyan, Chauvin, Alex Henri Jean, Cheshkov, Cvetan Valeriev, Cheynis, Brigitte, Chibante Barroso, Vasco Miguel, Dobrigkeit Chinellato, David, Cho, Soyeon, Alessandro, Bruno, Chochula, Peter, Chowdhury, Tasnuva, Christakoglou, Panagiotis, Christensen, Christian Holm, Christiansen, Peter, Chujo, Tatsuya, Cicalo, Corrado, Cifarelli, Luisa, De Cilladi, Lorenzo, Cindolo, Federico, Alfanda, Haidar Mas'ud, Ciupek, Michael Rudolf, Clai, Giulia, Cleymans, Jean Willy Andre, Colamaria, Fabio Filippo, Colella, Domenico, Collu, Alberto, Colocci, Manuel, Concas, Matteo, Conesa Balbastre, Gustavo, Conesa Del Valle, Zaida, Alfaro Molina, Jose Ruben, Contin, Giacomo, Contreras Nuno, Jesus Guillermo, Cormier, Thomas Michael, Corrales Morales, Yasser, Cortese, Pietro, Cosentino, Mauro Rogerio, Costa, Filippo, Costanza, Susanna, Crochet, Philippe, Cuautle Flores, Eleazar, Adler, Alexander, Ali, Bushra, Cui, Pengyao, Cunqueiro Mendez, Leticia, Dabrowski, Daniel, Dahms, Torsten, Dainese, Andrea, Damas, Florian Paul Andre, Danisch, Meike Charlotte, Danu, Andrea, Das, Debasish, Das, Indranil, Ali, Yasir, Das, Prottay, Das, Prottoy, Das, Supriya, Dash, Ajay Kumar, Dash, Sadhana, De, Sudipan, De Caro, Annalisa, De Cataldo, Giacinto, De Cuveland, Jan, De Falco, Alessandro, Alici, Andrea, De Gruttola, Daniele, De Marco, Nora, De Pasquale, Salvatore, Deb, Suman, Franz Degenhardt, Hermann, Deja, Kamil Rafal, Deloff, Andrzej, Delsanto, Silvia, Deng, Wenjing, Dhankher, Preeti, Alizadehvandchali, Negin, Di Bari, Domenico, Di Mauro, Antonio, Arteche Diaz, Raul, Dietel, Thomas, Raisig, Pascal, Ding, Yanchun, Divia, Roberto, Dixit, Dhruv Utpalkumar, Djuvsland, Oeystein, Dmitrieva, Uliana, Alkin, Anton, Dobrin, Alexandru Florin, Donigus, Benjamin, Dordic, Olja, Dubey, Anand Kumar, Dubla, Andrea, Dudi, Sandeep, Mallick, Dukhishyam, Dupieux, Pascal, Ehlers Iii, Raymond James, Eikeland, Viljar Nilsen, Alme, Johan, Elia, Domenico, Erazmus, Barbara Ewa, Erhardt, Filip, Erokhin, Andrey, Ersdal, Magnus Rentsch, Espagnon, Bruno, Eulisse, Giulio, Evans, David, Evdokimov, Sergey, Fabbietti, Laura, Alt, Torsten, Faggin, Mattia, Faivre, Julien, Fan, Feng, Fantoni, Alessandra, Fasel, Markus, Fecchio, Pietro, Feliciello, Alessandro, Feofilov, Grigorii, Fernandez Tellez, Arturo, Ferrero, Andrea, Altenkamper, Lucas, Ferretti, Alessandro, Festanti, Andrea, Feuillard, Victor Jose Gaston, Figiel, Jan, Filchagin, Sergey, Finogeev, Dmitry, Fionda, Fiorella, Fiorenza, Gabriele, Flor, Fernando Antonio, Flores, Amanda Nicole, Altsybeev, Igor, Foertsch, Siegfried Valentin, Foka, Panagiota, Fokin, Sergey, Fragiacomo, Enrico, Frankenfeld, Ulrich Michael, Fuchs, Ulrich, Furget, Christophe, Furs, Artur, Fusco Girard, Mario, Gaardhoeje, Jens Joergen, Anaam, Mustafa, Gagliardi, Martino, Gago Medina, Alberto Martin, Gal, Arthur Willem Jean, Duarte Galvan, Carlos, Ganoti, Paraskevi, Garabatos Cuadrado, Jose, Alvarado Garcia, Jesus Ricardo, Garcia-solis, Edmundo Javier, Garg, Kunal, Gargiulo, Corrado, Adolfsson, Jonatan, Andrei, Cristian, Garibli, Aydan, Garner, Katharina, Gasik, Piotr Jan, Gauger, Erin Frances, De Leone Gay, Maria Beatriz, Germain, Marie, Ghosh, Jhuma, Ghosh, Premomoy, Ghosh, Sanjay Kumar, Giacalone, Marco, Andreou, Dimitra, Gianotti, Paola, Giubellino, Paolo, Giubilato, Piero, Glaenzer, Aude Marie Camille, Glassel, Peter, Gomez Ramirez, Andres, Gonzalez, Victor, Gonzalez Trueba, Laura Helena, Gorbunov, Sergey, Gorlich, Lidia Maria, Andronic, Anton, Goswami, Ankita, Gotovac, Sven, Grabski, Varlen, Graczykowski, Lukasz Kamil, Graham, Katie Leanne, Greiner, Leo Clifford, Grelli, Alessandro, Grigoras, Costin, Grigoryev, Vladislav, Grigoryan, Ara, Angeletti, Massimo, Grigoryan, Smbat, Groettvik, Ola Slettevoll, Grosa, Fabrizio, Grosse-oetringhaus, Jan Fiete, Grosso, Raffaele, Guernane, Rachid, Guittiere, Manuel, Gulbrandsen, Kristjan Herlache, Gunji, Taku, Gupta, Anik, Anguelov, Venelin, Gupta, Ramni, Bautista Guzman, Irais, Haake, Rudiger, Habib, Michael Karim, Hadjidakis, Cynthia Marie, Hamagaki, Hideki, Hamar, Gergoe, Hamid, Mohammed, Hannigan, Ryan Patrick, Haque, Md Rihan, Anson, Christopher Daniel, Harlenderova, Alena, Harris, John William, Harton, Austin Vincent, Hasenbichler, Jan Anton, Hassan, Hadi, Hassan, Qamar Ul, Hatzifotiadou, Despina, Hauer, Philip, Havener, Laura Brittany, Hayashi, Shinichi, Anticic, Tome, Heckel, Stefan Thomas, Hellbar, Ernst, Helstrup, Haavard, Herghelegiu, Andrei Ionut, Herman, Tomas, Gonzalez Hernandez, Emma, Herrera Corral, Gerardo Antonio, Herrmann, Florian, Hetland, Kristin Fanebust, Hillemanns, Hartmut, Antinori, Federico, Hills, Christopher, Hippolyte, Boris, Hohlweger, Bernhard, Honermann, Jan, Horak, David, Hornung, Andrea, Hornung, Sebastian, Hosokawa, Ritsuya, Hristov, Peter Zahariev, Huang, Chun-lu, Antonioli, Pietro, Hughes, Charles, Huhn, Patrick, Humanic, Thomas, Hushnud, Hushnud, Husova, Lucia Anna, Hussain, Nur, Hussain, Syed Asad, Hutter, Dirk, Iddon, James Philip, Ilkaev, Radiy, Apadula, Nicole, Ilyas, Hira, Inaba, Motoi, Innocenti, Gian Michele, Ippolitov, Mikhail, Isakov, Artem, Islam, Md Samsul, Ivanov, Marian, Ivanov, Vladimir, Izucheev, Vladimir, Jacak, Barbara, Aggarwal, Madan Mohan, Aphecetche, Laurent Bernard, Jacazio, Nicolo, Jacobs, Peter Martin, Jadlovska, Slavka, Jadlovsky, Jan, Jaelani, Syaefudin, Jahnke, Cristiane, Jakubowska, Monika Joanna, Janik, Malgorzata Anna, Janson, Thomas, Jercic, Marko, Appelshaeuser, Harald, Jevons, Oliver Thomas, Jin, Muqing, Jonas, Florian, Jones, Peter Graham, Jung, Jerome, Jung, Michael, Jusko, Anton, Kalinak, Peter, Kalweit, Alexander Philipp, Kaplin, Vladimir, Arcelli, Silvia, Kar, Somnath, Karasu Uysal, Ayben, Karatovic, David, Karavichev, Oleg, Karavicheva, Tatiana, Karczmarczyk, Przemyslaw, Karpechev, Evgeny, Kazantsev, Andrey, Kebschull, Udo Wolfgang, Keidel, Ralf, Arnaldi, Roberta, Keil, Markus, Ketzer, Bernhard Franz, Khabanova, Zhanna, Khan, Ahsan Mehmood, Khan, Shaista, Khanzadeev, Alexei, Kharlov, Yury, Khatun, Anisa, Khuntia, Arvind, Kileng, Bjarte, Arratia Munoz, Miguel Ignacio, Kim, Beomkyu, Kim, Byungchul, Kim, Daehyeok, Kim, Dong Jo, Kim, Eun Joo, Kim, Hyeonjoong, Kim, Jaehyun, Kim, Jinsook, Kim, Jiyoung, Kim, Jungeol, Arsene, Ionut Cristian, Kim, Junlee, Kim, Minjung, Kim, Se Yong, Kim, Taejun, Kim, Taesoo, Kirsch, Stefan, Kisel, Ivan, Kiselev, Sergey, Kisiel, Adam Ryszard, Klay, Jennifer Lynn, Arslandok, Mesut, Klein, Carsten, Klein, Jochen, Klein, Spencer Robert, Klein-boesing, Christian, Kleiner, Matthias, Kluge, Alexander, Knichel, Michael Linus, Knospe, Anders Garritt, Kobdaj, Chinorat, Kohler, Markus Konrad, Augustinus, Andre, Kollegger, Thorsten Sven, Kondratyev, Andrey, Kondratyeva, Natalia, Kondratyuk, Evgeny, Konig, Joshua Leon, Konigstorfer, Stephan Alexander, Konopka, Piotr Jan, Kornakov, Georgui, Koska, Lukas, Kovalenko, Oleksandr, Averbeck, Ralf Peter, Kovalenko, Vladimir, Kowalski, Marek, Kralik, Ivan, Kravcakova, Adela, Kreis, Lukas, Krivda, Marian, Krizek, Filip, Krizkova Gajdosova, Katarina, Kruger, Mario, Kryshen, Evgeny, Aziz, Sizar, Krzewicki, Mikolaj, Kubera, Andrew Michael, Kucera, Vit, Kuhn, Christian Claude, Kuijer, Paulus Gerardus, Kumar, Lokesh, Kundu, Sourav, Kurashvili, Podist, Kurepin, Alexander, Kurepin, Alexey, Aglieri Rinella, Gianluca, Azmi, Mohd Danish, Kuryakin, Alexey, Kushpil, Svetlana, Kvapil, Jakub, Kweon, Min Jung, Kwon, Jiyeon, Kwon, Youngil, La Pointe, Sarah Louise, La Rocca, Paola, Lai, Yue Shi, Lamanna, Massimo, Badala, Angela, Langoy, Rune, Lapidus, Kirill, Lardeux, Antoine Xavier, Larionov, Pavel, Laudi, Elisa, Lavicka, Roman, Lazareva, Tatiana, Lea, Ramona, Leardini, Lucia, Lee, Joonil, Baek, Yongwook, Lee, Seongjoo, Lehner, Sebastian, Lehrbach, Johannes, Lemmon, Roy Crawford, Leon Monzon, Ildefonso, Lesser, Ezra Douglas, Lettrich, Michael, Levai, Peter, Li, Xiaomei, Li, Xing Long, Bagnasco, Stefano, Lien, Jorgen Andre, Lietava, Roman, Lim, Bong-hwi, Lindenstruth, Volker, Lindner, Amelia, Lippmann, Christian, Lisa, Michael Annan, Liu, Alwina Ruixin, Liu, Jian, Liu, Suyuan, Bai, Xiaozhi, Llope, William Joseph, Lofnes, Ingrid Mckibben, Loginov, Vitaly, Loizides, Constantinos, Loncar, Petra, Lopez Lopez, Jorge Andres, Lopez, Xavier Bernard, Lopez Torres, Ernesto, Luhder, Jens Robert, Lunardon, Marcello, Bailhache, Raphaelle Marie, Luparello, Grazia, Ma, Yugang, Maevskaya, Alla, Mager, Magnus, Mahmood, Sohail Musa, Mahmoud, Tariq, Maire, Antonin, Majka, Richard Daniel, Malaev, Mikhail, Malik, Qasim Waheed, Bala, Renu, Malinina, Liudmila, Mal Kevich, Dmitry, Malzacher, Peter, Mandaglio, Giuseppe, Manko, Vladislav, Manso, Franck, Manzari, Vito, Mao, Yaxian, Marchisone, Massimiliano, Mares, Jiri, Balbino, Alessandro, Margagliotti, Giacomo Vito, Margotti, Anselmo, Marin, Ana Maria, Markert, Christina, Marquard, Marco, De Martin, Chiara, Martin, Nicole Alice, Martinengo, Paolo, Martinez, Jacobb Lee, Martinez Hernandez, Mario Ivan, Baldisseri, Alberto, Martinez-garcia, Gines, Masciocchi, Silvia, Masera, Massimo, Masoni, Alberto, Massacrier, Laure Marie, Masson, Erwann, Mastroserio, Annalisa, Mathis, Andreas Michael, Matonoha, Oliver, Toledo Matuoka, Paula Fernanda, Ball, Markus, Matyja, Adam Tomasz, Mayer, Christoph, Mazzaschi, Francesco, Mazzilli, Marianna, Mazzoni, Alessandra Maria, Mechler, Adrian Florin, Meddi, Franco, Melikyan, Yury, Menchaca-rocha, Arturo Alejandro, Cai, Mengke, Agnello, Michelangelo, Balouza, Samah, Meninno, Elisa, Sasikumar Menon, Anjaly, Meres, Michal, Mhlanga, Sibaliso, Miake, Yasuo, Micheletti, Luca, Migliorin, Lucrezia Camilla, Mihaylov, Dimitar Lubomirov, Mikhaylov, Konstantin, Mishra, Aditya Nath, Banerjee, Debjani, Miskowiec, Dariusz Czeslaw, Modak, Abhi, Mohammadi, Naghmeh, Mohanty, Auro Prasad, Mohanty, Bedangadas, Khan, Mohammed Mohisin, Moravcova, Zuzana, Mordasini, Cindy, Moreira De Godoy, Denise Aparecida, Perez Moreno, Luis Alberto, Barbera, Roberto, Morozov, Igor, Morsch, Andreas, Mrnjavac, Teo, Muccifora, Valeria, Mudnic, Eugen, Muhlheim, Daniel Michael, Muhuri, Sanjib, Mulligan, James Declan, Mulliri, Alice, Gameiro Munhoz, Marcelo, Barioglio, Luca, Munzer, Robert Helmut, Murakami, Hikari, Murray, Sean, Musa, Luciano, Musinsky, Jan, Myers, Corey James, Myrcha, Julian Wojciech, Naik, Bharati, Nair, Rahul Ramachandran, Nandi, Basanta Kumar, Barnafoldi, Gergely Gabor, Nania, Rosario, Nappi, Eugenio, Naru, Muhammad Umair, Nassirpour, Adrian Fereydon, Nattrass, Christine, Nayak, Ranjit, Nayak, Tapan Kumar, Nazarenko, Sergey, Neagu, Alexandra, Negrao De Oliveira, Renato Aparecido, Barnby, Lee Stuart, Nellen, Lukas, Nesbo, Simon Voigt, Neskovic, Gvozden, Nesterov, Dmitrii, Neumann, Lukasz Tomasz, Nielsen, Borge Svane, Nikolaev, Sergey, Nikulin, Sergey, Nikulin, Vladimir, Noferini, Francesco, Ramillien Barret, Valerie, Nomokonov, Petr, Norman, Jaime, Novitzky, Norbert, Nowakowski, Piotr, Nyanin, Alexander, Nystrand, Joakim Ingemar, Ogino, Masanori, Ohlson, Alice Elisabeth, Oleniacz, Janusz, Oliveira Da Silva, Antonio Carlos, Bartalini, Paolo, Oliver, Michael Henry, Oppedisano, Chiara, Ortiz Velasquez, Antonio, Oskarsson, Anders Nils Erik, Otwinowski, Jacek Tomasz, Oyama, Ken, Pachmayer, Yvonne Chiara, Pacik, Vojtech, Padhan, Sonali, Pagano, Davide, Bartels, Clara, Paic, Guy, Pan, Jinjin, Panebianco, Stefano, Pareek, Pooja, Park, Jonghan, Parkkila, Jasper Elias, Parmar, Sonia, Pathak, Surya Prakash, Paul, Biswarup, Pazzini, Jacopo, Barth, Klaus, Pei, Hua, Peitzmann, Thomas, Peng, Xinye, Pereira, Luis Gustavo, Pereira Da Costa, Hugo Denis Antonio, Peresunko, Dmitry Yurevich, Mesa Perez, Guillermo, Perrin, Sebastien, Pestov, Yury, Petracek, Vojtech, Agrawal, Neelima, Bartsch, Esther, Petrovici, Mihai, Peretti Pezzi, Rafael, Piano, Stefano, Pikna, Miroslav, Pillot, Philippe, Pinazza, Ombretta, Pinsky, Lawrence, Pinto, Chiara, Pisano, Silvia, Pistone, Daniele, Baruffaldi, Filippo, Ploskon, Mateusz Andrzej, Planinic, Mirko, Pliquett, Fabian, Poghosyan, Martin, Polishchuk, Boris, Poljak, Nikola, Pop, Amalia, Porteboeuf, Sarah Julie, Pozdniakov, Valeriy, Prasad, Sidharth Kumar, Bastid, Nicole, Preghenella, Roberto, Prino, Francesco, Pruneau, Claude Andre, Pshenichnov, Igor, Puccio, Maximiliano, Putschke, Jorn Henning, Qiu, Shi, Quaglia, Luca, Quishpe Quishpe, Raquel Estefania, Ragoni, Simone, Basu, Sumit, Raha, Sibaji, Rajput, Sonia, Rak, Jan, Rakotozafindrabe, Andry Malala, Ramello, Luciano, Rami, Fouad, Rodriguez Ramirez, Saul Anibal, Raniwala, Rashmi, Raniwala, Sudhir, Rasanen, Sami Sakari, Batigne, Guillaume, Rath, Rutuparna, Ratza, Viktor, Ravasenga, Ivan, Read, Kenneth Francis, Redelbach, Andreas Ralph, Redlich, Krzysztof, Rehman, Attiq Ur, Reichelt, Patrick Simon, Reidt, Felix, Ren, Xiaowen, Batyunya, Boris, Renfordt, Rainer Arno Ernst, Jakubcinova, Zuzana, Reygers, Klaus Johannes, Riabov, Andrei, Riabov, Viktor, Richert, Tuva Ora Herenui, Richter, Matthias Rudolph, Riedler, Petra, Riegler, Werner, Riggi, Francesco, Bauri, Dibakar, Ristea, Catalin-lucian, Rode, Sudhir Pandurang, Rodriguez Cahuantzi, Mario, Roeed, Ketil, Rogalev, Roman, Rogochaya, Elena, Rohr, David Michael, Roehrich, Dieter, Fierro Rojas, Pablo, Rokita, Przemyslaw Stefan, Bazo Alba, Jose Luis, Ronchetti, Federico, Rosano, Antonina, Dominguez Rosas, Edgar, Roslon, Krystian, Rossi, Andrea, Rotondi, Alberto, Roy, Ankhi, Roy, Pradip Kumar, Vazquez Rueda, Omar, Rui, Rinaldo, Bearden, Ian Gardner, Rumyantsev, Boris, Rustamov, Anar, Ryabinkin, Evgeny, Ryabov, Yury, Rybicki, Andrzej, Rytkonen, Heidi Maria, Saarimaki, Oskari Antti Matti, Sadek, Rita, Sadhu, Samrangy, Sadovskiy, Sergey, Beattie, Caitlin, Safarik, Karel, Saha, Sumit Kumar, Sahoo, Baidyanath, Sahoo, Pragati, Sahoo, Raghunath, Sahoo, Sarita, Sahu, Pradip Kumar, Saini, Jogender, Sakai, Shingo, Sambyal, Sanjeev Singh, Ahammed, Zubayer, Bedda, Cristina, Samsonov, Vladimir, Sarkar, Debojit, Sarkar, Nachiketa, Sarma, Pranjal, Mantovani Sarti, Valentina, Sas, Mike Henry Petrus, Scapparone, Eugenio, Schambach, Johann Joachim, Scheid, Horst Sebastian, Schiaua, Claudiu Cornel, Behera, Nirbhay Kumar, Schicker, Rainer Martin, Schmah, Alexander, Schmidt, Christian Joachim, Schmidt, Hans Rudolf, Schmidt, Marten Ole, Schmidt, Martin, Schmidt, Nicolas, Schmier, Austin Robert, Schukraft, Jurgen, Schutz, Yves Roland, Belikov, Iouri, Schwarz, Kilian Eberhard, Schweda, Kai Oliver, Scioli, Gilda, Scomparin, Enrico, Seger, Janet Elizabeth, Sekiguchi, Yuko, Sekihata, Daiki, Selyuzhenkov, Ilya, Senyukov, Serhiy, Serebryakov, Dmitry, Bell Hechavarria, Ailec, Sevcenco, Adrian, Shabanov, Arseniy, Shabetai, Alexandre, Shahoyan, Ruben, Shaikh, Wadut, Shangaraev, Artem, Sharma, Anjali, Sharma, Ankita, Sharma, Himanshu, Sharma, Meenakshi, Bellini, Francesca, Sharma, Natasha, Sharma, Sheetal, Sheibani, Oveis, Shigaki, Kenta, Hachiya Shimomura, Maya, Shirinkin, Sergey, Shou, Qiye, Sibiryak, Yury, Siddhanta, Sabyasachi, Siemiarczuk, Teodor, Bellwied, Rene, Silvermyr, David Olle Rickard, Simatovic, Goran, Simonetti, Giuseppe, Singh, Bhawani, Singh, Ranbir, Singh, Randhir, Singh, Ravindra, Singh, Vivek, Singhal, Vikas, Sarkar - Sinha, Tinku, Belyaev, Vladimir, Sitar, Branislav, Sitta, Mario, Skaali, Bernhard, Slupecki, Maciej, Smirnov, Nikolai, Snellings, Raimond, Soncco Meza, Carlos, Song, Jihye, Songmoolnak, Arnon, Soramel, Francesca, Bencedi, Gyula, Sorensen, Soren Pontoppidan, Sputowska, Iwona Anna, Stachel, Johanna, Stan, Ionel, Steffanic, Patrick John, Stenlund, Evert Anders, Stiefelmaier, Stephan Friedrich, Stocco, Diego, Storetvedt, Maksim Melnik, Dello Stritto, Luigi, Beole, Stefania, Alarcon Do Passo Suaide, Alexandre, Sugitate, Toru, Suire, Christophe Pierre, Suleymanov, Mais Kazim Oglu, Suljic, Miljenko, Sultanov, Rishat, Sumbera, Michal, Sumberia, Vikash, Sumowidagdo, Suharyo, Swain, Sagarika, Bercuci, Alexandru, Szabo, Alexander, Szarka, Imrich, Tabassam, Uzma, Taghavi, Seyed Farid, Taillepied, Guillaume, Takahashi, Jun, Tambave, Ganesh Jagannath, Tang, Siyu, Tarhini, Mohamad, Tarzila, Madalina-gabriela, Ahmad, Shakeel, Berdnikov, Yaroslav, Tauro, Arturo, Tejeda Munoz, Guillermo, Telesca, Adriana, Terlizzi, Livia, Terrevoli, Cristina, Thakur, Dhananjaya, Thakur, Sanchari, Thomas, Deepa, Thoresen, Freja, Tieulent, Raphael Noel, Berenyi, Daniel, Tikhonov, Anatoly, Timmins, Anthony Robert, Toia, Alberica, Topilskaya, Nataliya, Toppi, Marco, Torales Acosta, Fernando, Rojas Torres, Solangel, Trifiro, Antonio, Tripathy, Sushanta, Tripathy, Tulika, Bertens, Redmer Alexander, Trogolo, Stefano, Trombetta, Giuseppe, Tropp, Lukas, Trubnikov, Victor, Trzaska, Wladyslaw Henryk, Trzcinski, Tomasz Piotr, Trzeciak, Barbara Antonina, Tumkin, Alexandr, Turrisi, Rosario, Tveter, Trine Spedstad, Berzano, Dario, Ullaland, Kjetil, Umaka, Ejiro Naomi, Uras, Antonio, Usai, Gianluca, Vala, Martin, Valle, Nicolo', Vallero, Sara, Van Der Kolk, Naomi, Van Doremalen, Lennart, Van Leeuwen, Marco, Besoiu, Mihaela Gabriela, Vande Vyvre, Pierre, Varga, Dezso, Varga, Zoltan, Varga-kofarago, Monika, Diozcora Vargas Trevino, Aurora, Vasileiou, Maria, Vasiliev, Andrey, Vazquez Doce, Oton, Vechernin, Vladimir, Vercellin, Ermanno, Betev, Latchezar, Vergara Limon, Sergio, Vermunt, Lucas Anne, Vernet, Renaud, Vertesi, Robert, Vickovic, Linda, Vilakazi, Zabulon, Villalobos Baillie, Orlando, Vino, Gioacchino, Vinogradov, Alexander, Virgili, Tiziano, Bhasin, Anju, Vislavicius, Vytautas, Vodopyanov, Alexander, Volkel, Benedikt, Volkl, Martin Andreas, Voloshin, Kirill, Voloshin, Sergey, Volpe, Giacomo, Von Haller, Barthelemy, Vorobyev, Ivan, Voscek, Dominik, Bhat, Inayat Rasool, Vrlakova, Janka, Wagner, Boris, Weber, Michael, Weber, Steffen Georg, Wegrzynek, Adam Tadeusz, Wenzel, Sandro Christian, Wessels, Johannes Peter, Wiechula, Jens, Wikne, Jon, Wilk, Grzegorz Andrzej, Bhat, Mohammad Asif, Wilkinson, Jeremy John, Willems, Guido Alexander, Willsher, Emily Jade, Windelband, Bernd Stefan, Winn, Michael Andreas, Witt, William Edward, Wright, Josephina Rae, Wu, Yitao, Xu, Ran, Yalcin Kuzu, Serpil, Bhatt, Himani, Yamaguchi, Yorito, Yamakawa, Kosei, Yang, Shiming, Yano, Satoshi, Yin, Zhongbao, Yokoyama, Hiroki, Yoo, In Kwon, Yoon, Jin Hee, Yuan, Shiming, Yuncu, Alperen, Acharya, S., Adamova, D., Adler, A., Adolfsson, J., Aggarwal, M. M., Rinella, G. A., Agnello, M., Agrawal, N., Ahammed, Z., Ahmad, S., Ahn, S. U., Akbar, Z., Akindinov, A., Al-Turany, M., Alam, S. N., Albuquerque, D. S. D., Aleksandrov, D., Alessandro, B., Alfanda, H. M., Molina, R. A., Ali, B., Ali, Y., Alici, A., Alizadehvandchali, N., Alkin, A., Alme, J., Alt, T., Altenkamper, L., Altsybeev, I., Anaam, M. N., Andrei, C., Andreou, D., Andronic, A., Angeletti, M., Anguelov, V., Anson, C., Anticic, T., Antinori, F., Antonioli, P., Apadula, N., Aphecetche, L., Appelshauser, H., Arcelli, S., Arnaldi, R., Arratia, M., Arsene, I. C., Arslandok, M., Augustinus, A., Averbeck, R., Aziz, S., Azmi, M. D., Badala, A., Baek, Y. W., Bagnasco, S., Bai, X., Bailhache, R., Bala, R., Balbino, A., Baldisseri, A., Ball, M., Balouza, S., Banerjee, D., Barbera, R., Barioglio, L., Barnafoldi, G. G., Barnby, L. S., Barret, V., Bartalini, P., Bartels, C., Barth, K., Bartsch, E., Baruffaldi, F., Bastid, N., Basu, S., Batigne, G., Batyunya, B., Bauri, D., Alba, J. L. B., Bearden, I. G., Beattie, C., Bedda, C., Behera, N. K., Belikov, I., Hechavarria, A. D. C. B., Bellini, F., Bellwied, R., Belyaev, V., Bencedi, G., Beole, S., Bercuci, A., Berdnikov, Y., Berenyi, D., Bertens, R. A., Berzano, D., Besoiu, M. G., Betev, L., Bhasin, A., Bhat, I. R., Bhat, M. A., Bhatt, H., Bhattacharjee, B., Bianchi, A., Bianchi, L., Bianchi, N., Bielcik, J., Bielcikova, J., Bilandzic, A., Biro, G., Biswas, R., Biswas, S., Blair, J. T., Blau, D., Blume, C., Boca, G., Bock, F., Bogdanov, A., Boi, S., Bok, J., Boldizsar, L., Bolozdynya, A., Bombara, M., Bonomi, G., Borel, H., Borissov, A., Bossi, H., Botta, E., Bratrud, L., Braun-Munzinger, P., Bregant, M., Broz, M., Bruna, E., Bruno, G. E., Buckland, M. D., Budnikov, D., Buesching, H., Bufalino, S., Bugnon, O., Buhler, P., Buncic, P., Buthelezi, Z., Butt, J. B., Bysiak, S. A., Caffarri, D., Caliva, A., Villar, E. C., Camacho, J. M. M., Camacho, R. S., Camerini, P., Canedo, F. D. M., Capon, A. A., Carnesecchi, F., Caron, R., Castellanos, J. C., Castro, A. J., Casula, E. A. R., Catalano, F., Sanchez, C. C., Chakraborty, P., Chandra, S., Chang, W., Chapeland, S., Chartier, M., Chattopadhyay, S., Chauvin, A., Cheshkov, C., Cheynis, B., Barroso, V. C., Chinellato, D. D., Cho, S., Chochula, P., Chowdhury, T., Christakoglou, P., Christensen, C. H., Christiansen, P., Chujo, T., Cicalo, C., Cifarelli, L., Cilladi, L. D., Cindolo, F., Ciupek, M. R., Clai, G., Cleymans, J., Colamaria, F., Colella, D., Collu, A., Colocci, M., Concas, M., Balbastre, G. C., del Valle, Z. C., Contin, G., Contreras, J. G., Cormier, T. M., Morales, Y. C., Cortese, P., Cosentino, M. R., Costa, F., Costanza, S., Crochet, P., Cuautle, E., Cui, P., Cunqueiro, L., Dabrowski, D., Dahms, T., Dainese, A., Damas, F. P. A., Danisch, M. C., Danu, A., Das, D., Das, I., Das, P., Das, S., Dash, A., Dash, S., De, S., De Caro, A., de Cataldo, G., de Cuveland, J., De Falco, A., De Gruttola, D., De Marco, N., De Pasquale, S., Deb, S., Degenhardt, H. F., Deja, K. R., Deloff, A., Delsanto, S., Deng, W., Dhankher, P., Di Bari, D., Di Mauro, A., Diaz, R. A., Dietel, T., Dillenseger, P., Ding, Y., Divia, R., Dixit, D. U., Djuvsland, O., Dmitrieva, U., Dobrin, A., Donigus, B., Dordic, O., Dubey, A. K., Dubla, A., Dudi, S., Dukhishyam, M., Dupieux, P., Ehlers, R. J., Eikeland, V. N., Elia, D., Erazmus, B., Erhardt, F., Erokhin, A., Ersdal, M. R., Espagnon, B., Eulisse, G., Evans, D., Evdokimov, S., Fabbietti, L., Faggin, M., Faivre, J., Fan, F., Fantoni, A., Fasel, M., Fecchio, P., Feliciello, A., Feofilov, G., Tellez, A. F., Ferrero, A., Ferretti, A., Festanti, A., Feuillard, V. J. G., Figiel, J., Filchagin, S., Finogeev, D., Fionda, F. M., Fiorenza, G., Flor, F., Flores, A. N., Foertsch, S., Foka, P., Fokin, S., Fragiacomo, E., Frankenfeld, U., Fuchs, U., Furget, C., Furs, A., Girard, M. F., Gaardhoje, J. J., Gagliardi, M., Gago, A. M., Gal, A., Galvan, C. D., Ganoti, P., Garabatos, C., Garcia, J. R. A., Garcia-Solis, E., Garg, K., Gargiulo, C., Garibli, A., Garner, K., Gasik, P., Gauger, E. F., Ducati, M. B. G., Germain, M., Ghosh, J., Ghosh, P., Ghosh, S. K., Giacalone, M., Gianotti, P., Giubellino, P., Giubilato, P., Glaenzer, A. M. C., Glassel, P., Ramirez, A. G., Gonzalez, V., Gonzalez-Trueba, L. H., Gorbunov, S., Gorlich, L., Goswami, A., Gotovac, S., Grabski, V., Graczykowski, L. K., Graham, K. L., Greiner, L., Grelli, A., Grigoras, C., Grigoriev, V., Grigoryan, A., Grigoryan, S., Groettvik, O. S., Grosa, F., Grosse-Oetringhaus, J. F., Grosso, R., Guernane, R., Guittiere, M., Gulbrandsen, K., Gunji, T., Gupta, A., Gupta, R., Guzman, I. B., Haake, R., Habib, M. K., Hadjidakis, C., Hamagaki, H., Hamar, G., Hamid, M., Hannigan, R., Haque, M. R., Harlenderova, A., Harris, J. W., Harton, A., Hasenbichler, J. A., Hassan, H., Hassan, Q. U., Hatzifotiadou, D., Hauer, P., Havener, L. B., Hayashi, S., Heckel, S. T., Hellbar, E., Helstrup, H., Herghelegiu, A., Herman, T., Hernandez, E. G., Corral, G. H., Herrmann, F., Hetland, K. F., Hillemanns, H., Hills, C., Hippolyte, B., Hohlweger, B., Honermann, J., Horak, D., Hornung, A., Hornung, S., Hosokawa, R., Hristov, P., Huang, C., Hughes, C., Huhn, P., Humanic, T. J., Hushnud, H., Husova, L. A., Hussain, N., Hussain, S. A., Hutter, D., Iddon, J. P., Ilkaev, R., Ilyas, H., Inaba, M., Innocenti, G. M., Ippolitov, M., Isakov, A., Islam, M. S., Ivanov, M., Ivanov, V., Izucheev, V., Jacak, B., Jacazio, N., Jacobs, P. M., Jadlovska, S., Jadlovsky, J., Jaelani, S., Jahnke, C., Jakubowska, M. J., Janik, M. A., Janson, T., Jercic, M., Jevons, O., Jin, M., Jonas, F., Jones, P. G., Jung, J., Jung, M., Jusko, A., Kalinak, P., Kalweit, A., Kaplin, V., Kar, S., Uysal, A. K., Karatovic, D., Karavichev, O., Karavicheva, T., Karczmarczyk, P., Karpechev, E., Kazantsev, A., Kebschull, U., Keidel, R., Keil, M., Ketzer, B., Khabanova, Z., Khan, A. M., Khan, S., Khanzadeev, A., Kharlov, Y., Khatun, A., Khuntia, A., Kileng, B., Kim, B., Kim, D., Kim, D. J., Kim, E. J., Kim, H., Kim, J., Kim, J. S., Kim, M., Kim, S., Kim, T., Kirsch, S., Kisel, I., Kiselev, S., Kisiel, A., Klay, J. L., Klein, C., Klein, J., Klein, S., Klein-Bosing, C., Kleiner, M., Kluge, A., Knichel, M. L., Knospe, A. G., Kobdaj, C., Kohler, M. K., Kollegger, T., Kondratyev, A., Kondratyeva, N., Kondratyuk, E., Konig, J., Konigstorfer, S. A., Konopka, P. J., Kornakov, G., Koska, L., Kovalenko, O., Kovalenko, V., Kowalski, M., Kralik, I., Kravcakova, A., Kreis, L., Krivda, M., Krizek, F., Gajdosova, K. K., Kruger, M., Kryshen, E., Krzewicki, M., Kubera, A. M., Kucera, V., Kuhn, C., Kuijer, P. G., Kumar, L., Kundu, S., Kurashvili, P., Kurepin, A., Kurepin, A. B., Kuryakin, A., Kushpil, S., Kvapil, J., Kweon, M. J., Kwon, J. Y., Kwon, Y., La Pointe, S. L., La Rocca, P., Lai, Y. S., Lamanna, M., Langoy, R., Lapidus, K., Lardeux, A., Larionov, P., Laudi, E., Lavicka, R., Lazareva, T., Lea, R., Leardini, L., Lee, J., Lee, S., Lehner, S., Lehrbach, J., Lemmon, R. C., Monzon, I. L., Lesser, E. D., Lettrich, M., Levai, P., Li, X., Li, X. L., Lien, J., Lietava, R., Lim, B., Lindenstruth, V., Lindner, A., Lippmann, C., Lisa, M. A., Liu, A., Liu, J., Liu, S., Llope, W. J., Lofnes, I. M., Loginov, V., Loizides, C., Loncar, P., Lopez, J. A., Lopez, X., Torres, E. L., Luhder, J. R., Lunardon, M., Luparello, G., Ma, Y. G., Maevskaya, A., Mager, M., Mahmood, S. M., Mahmoud, T., Maire, A., Majka, R. D., Malaev, M., Malik, Q. W., Malinina, L., Mal'Kevich, D., Malzacher, P., Mandaglio, G., Manko, V., Manso, F., Manzari, V., Mao, Y., Marchisone, M., Mares, J., Margagliotti, G. V., Margotti, A., Marin, A., Markert, C., Marquard, M., Martin, C. D., Martin, N. A., Martinengo, P., Martinez, J. L., Martinez, M. I., Garcia, G. M., Masciocchi, S., Masera, M., Masoni, A., Massacrier, L., Masson, E., Mastroserio, A., Mathis, A. M., Matonoha, O., Matuoka, P. F. T., Matyja, A., Mayer, C., Mazzaschi, F., Mazzilli, M., Mazzoni, M. A., Mechler, A. F., Meddi, F., Melikyan, Y., Menchaca-Rocha, A., Mengke, C., Meninno, E., Menon, A. S., Meres, M., Mhlanga, S., Miake, Y., Micheletti, L., Migliorin, L. C., Mihaylov, D. L., Mikhaylov, K., Mishra, A. N., Miskowiec, D., Modak, A., Mohammadi, N., Mohanty, A. P., Mohanty, B., Khan, M. M., Moravcova, Z., Mordasini, C., Moreira De Godoy, D. A., Moreno, L. A. P., Morozov, I., Morsch, A., Mrnjavac, T., Muccifora, V., Mudnic, E., Muhlheim, D., Muhuri, S., Mulligan, J. D., Mulliri, A., Munhoz, M. G., Munzer, R. H., Murakami, H., Murray, S., Musa, L., Musinsky, J., Myers, C. J., Myrcha, J. W., Naik, B., Nair, R., Nandi, B. K., Nania, R., Nappi, E., Naru, M. U., Nassirpour, A. F., Nattrass, C., Nayak, R., Nayak, T. K., Nazarenko, S., Neagu, A., Negrao De Oliveira, R. A., Nellen, L., Nesbo, S. V., Neskovic, G., Nesterov, D., Neumann, L. T., Nielsen, B. S., Nikolaev, S., Nikulin, S., Nikulin, V., Noferini, F., Nomokonov, P., Norman, J., Novitzky, N., Nowakowski, P., Nyanin, A., Nystrand, J., Ogino, M., Ohlson, A., Oleniacz, J., Da Silva, A. C. O., Oliver, M. H., Oppedisano, C., Velasquez, A. O., Oskarsson, A., Otwinowski, J., Oyama, K., Pachmayer, Y., Pacik, V., Padhan, S., Pagano, D., Paic, G., Pan, J., Panebianco, S., Pareek, P., Park, J., Parkkila, J. E., Parmar, S., Pathak, S. P., Paul, B., Pazzini, J., Pei, H., Peitzmann, T., Peng, X., Pereira, L. G., Da Costa, H. P., Peresunko, D., Perez, G. M., Perrin, S., Pestov, Y., Petracek, V., Petrovici, M., Pezzi, R. P., Piano, S., Pikna, M., Pillot, P., Pinazza, O., Pinsky, L., Pinto, C., Pisano, S., Pistone, D., Ploskon, M., Planinic, M., Pliquett, F., Poghosyan, M. G., Polichtchouk, B., Poljak, N., Pop, A., Porteboeuf-Houssais, S., Pozdniakov, V., Prasad, S. K., Preghenella, R., Prino, F., Pruneau, C. A., Pshenichnov, I., Puccio, M., Putschke, J., Qiu, S., Quaglia, L., Quishpe, R. E., Ragoni, S., Raha, S., Rajput, S., Rak, J., Rakotozafindrabe, A., Ramello, L., Rami, F., Ramirez, S. A. R., Raniwala, R., Raniwala, S., Rasanen, S. S., Rath, R., Ratza, V., Ravasenga, I., Read, K. F., Redelbach, A. R., Redlich, K., Rehman, A., Reichelt, P., Reidt, F., Ren, X., Renfordt, R., Rescakova, Z., Reygers, K., Riabov, A., Riabov, V., Richert, T., Richter, M., Riedler, P., Riegler, W., Riggi, F., Ristea, C., Rode, S. P., Cahuantzi, M. R., Roed, K., Rogalev, R., Rogochaya, E., Rohr, D., Rohrich, D., Rojas, P. F., Rokita, P. S., Ronchetti, F., Rosano, A., Rosas, E. D., Roslon, K., Rossi, A., Rotondi, A., Roy, A., Roy, P., Rueda, O. V., Rui, R., Rumyantsev, B., Rustamov, A., Ryabinkin, E., Ryabov, Y., Rybicki, A., Rytkonen, H., Saarimaki, O. A. M., Sadek, R., Sadhu, S., Sadovsky, S., Safarik, K., Saha, S. K., Sahoo, B., Sahoo, P., Sahoo, R., Sahoo, S., Sahu, P. K., Saini, J., Sakai, S., Sambyal, S., Samsonov, V., Sarkar, D., Sarkar, N., Sarma, P., Sarti, V. M., Sas, M. H. P., Scapparone, E., Schambach, J., Scheid, H. S., Schiaua, C., Schicker, R., Schmah, A., Schmidt, C., Schmidt, H. R., Schmidt, M. O., Schmidt, M., Schmidt, N. V., Schmier, A. R., Schukraft, J., Schutz, Y., Schwarz, K., Schweda, K., Scioli, G., Scomparin, E., Seger, J. E., Sekiguchi, Y., Sekihata, D., Selyuzhenkov, I., Senyukov, S., Serebryakov, D., Sevcenco, A., Shabanov, A., Shabetai, A., Shahoyan, R., Shaikh, W., Shangaraev, A., Sharma, A., Sharma, H., Sharma, M., Sharma, N., Sharma, S., Sheibani, O., Shigaki, K., Shimomura, M., Shirinkin, S., Shou, Q., Sibiriak, Y., Siddhanta, S., Siemiarczuk, T., Silvermyr, D., Simatovic, G., Simonetti, G., Singh, B., Singh, R., Singh, V. K., Singhal, V., Sinha, T., Sitar, B., Sitta, M., Skaali, T. B., Slupecki, M., Smirnov, N., Snellings, R. J. M., Soncco, C., Song, J., Songmoolnak, A., Soramel, F., Sorensen, S., Sputowska, I., Stachel, J., Stan, I., Steffanic, P. J., Stenlund, E., Stiefelmaier, S. F., Stocco, D., Storetvedt, M. M., Stritto, L. D., Suaide, A. A. P., Sugitate, T., Suire, C., Suleymanov, M., Suljic, M., Sultanov, R., Sumbera, M., Sumberia, V., Sumowidagdo, S., Swain, S., Szabo, A., Szarka, I., Tabassam, U., Taghavi, S. F., Taillepied, G., Takahashi, J., Tambave, G. J., Tang, S., Tarhini, M., Tarzila, M. G., Tauro, A., Munoz, G. T., Telesca, A., Terlizzi, L., Terrevoli, C., Thakur, D., Thakur, S., Thomas, D., Thoresen, F., Tieulent, R., Tikhonov, A., Timmins, A. R., Toia, A., Topilskaya, N., Toppi, M., Torales-Acosta, F., Torres, S. R., Trifiro, A., Tripathy, S., Tripathy, T., Trogolo, S., Trombetta, G., Tropp, L., Trubnikov, V., Trzaska, W. H., Trzcinski, T. P., Trzeciak, B. A., Tumkin, A., Turrisi, R., Tveter, T. S., Ullaland, K., Umaka, E. N., Uras, A., Usai, G. L., Vala, M., Valle, N., Vallero, S., van der Kolk, N., van Doremalen, L. V. R., van Leeuwen, M., Vyvre, P. V., Varga, D., Varga, Z., Varga-Kofarago, M., Vargas, A., Vasileiou, M., Vasiliev, A., Doce, O. V., Vechernin, V., Vercellin, E., Limon, S. V., Vermunt, L., Vernet, R., Vertesi, R., Vickovic, L., Vilakazi, Z., Baillie, O. V., Vino, G., Vinogradov, A., Virgili, T., Vislavicius, V., Vodopyanov, A., Volkel, B., Volkl, M. A., Voloshin, K., Voloshin, S. A., Volpe, G., von Haller, B., Vorobyev, I., Voscek, D., Vrlakova, J., Wagner, B., Weber, M., Weber, S. G., Wegrzynek, A., Wenzel, S. C., Wessels, J. P., Wiechula, J., Wikne, J., Wilk, G., Wilkinson, J., Willems, G. A., Willsher, E., Windelband, B., Winn, M., Witt, W. E., Wright, J. R., Wu, Y., Xu, R., Yalcin, S., Yamaguchi, Y., Yamakawa, K., Yang, S., Yano, S., Yin, Z., Yokoyama, H., Yoo, I. -K., Yoon, J. H., Yuan, S., Yuncu, A., Yurchenko, V., Zaccolo, V., Zaman, A., Zampolli, C., Zanoli, H. J. C., Zardoshti, N., Zarochentsev, A., Zavada, P., Zaviyalov, N., Zbroszczyk, H., Zhalov, M., Zhang, S., Zhang, X., Zhang, Z., Zherebchevskii, V., Zhi, Y., Zhou, D., Zhou, Y., Zhou, Z., Zhu, J., Zhu, Y., Zichichi, A., Zinovjev, G., Zurlo, N., Laboratoire de physique subatomique et des technologies associées (SUBATECH), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Laboratoire de Physique des 2 Infinis Irène Joliot-Curie (IJCLab), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Département de Physique Nucléaire (ex SPhN) (DPHN), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire de Physique de Clermont (LPC), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Institut Pluridisciplinaire Hubert Curien (IPHC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Centre de Calcul de l'IN2P3 (CC-IN2P3), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), ALICE, Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), S. Acharya, D. Adamová, A. Adler, J. Adolfsson, M. M. Aggarwal, G. Aglieri Rinella, M. Agnello, N. Agrawal, Z. Ahammed, S. Ahmad, S. U. Ahn, Z. Akbar, A. Akindinov, M. Al-Turany, S. N. Alam, D. S. D. Albuquerque, D. Aleksandrov, B. Alessandro, H. M. Alfanda, R. Alfaro Molina, B. Ali, Y. Ali, A. Alici, N. Alizadehvandchali, A. Alkin, J. Alme, T. Alt, L. Altenkamper, I. Altsybeev, M. N. Anaam, C. Andrei, D. Andreou, A. Andronic, M. Angeletti, V. Anguelov, C. Anson, T. Antičić, F. Antinori, P. Antonioli, N. Apadula, L. Aphecetche, H. Appelshäuser, S. Arcelli, R. Arnaldi, M. Arratia, I. C. Arsene, M. Arslandok, A. Augustinus, R. Averbeck, S. Aziz, M. D. Azmi, A. Badalà, Y. W. Baek, S. Bagnasco, X. Bai, R. Bailhache, R. Bala, A. Balbino, A. Baldisseri, M. Ball, S. Balouza, D. Banerjee, R. Barbera, L. Barioglio, G. G. Barnaföldi, L. S. Barnby, V. Barret, P. Bartalini, C. Bartels, K. Barth, E. Bartsch, F. Baruffaldi, N. Bastid, S. Basu, G. Batigne, B. Batyunya, D. Bauri, J. L. Bazo Alba, I. G. Bearden, C. Beattie, C. Bedda, N. K. Behera, I. Belikov, A. D. C. Bell Hechavarria, F. Bellini, R. Bellwied, V. Belyaev, G. Bencedi, S. Beole, A. Bercuci, Y. Berdnikov, D. Berenyi, R. A. Bertens, D. Berzano, M. G. Besoiu, L. Betev, A. Bhasin, I. R. Bhat, M. A. Bhat, H. Bhatt, B. Bhattacharjee, A. Bianchi, L. Bianchi, N. Bianchi, J. Bielčík, J. Bielčíková, A. Bilandzic, G. Biro, R. Biswas, S. Biswas, J. T. Blair, D. Blau, C. Blume, G. Boca, F. Bock, A. Bogdanov, S. Boi, J. Bok, L. Boldizsár, A. Bolozdynya, M. Bombara, G. Bonomi, H. Borel, A. Borissov, H. Bossi, E. Botta, L. Bratrud, P. Braun-Munzinger, M. Bregant, M. Broz, E. Bruna, G. E. Bruno, M. D. Buckland, D. Budnikov, H. Buesching, S. Bufalino, O. Bugnon, P. Buhler, P. Buncic, Z. Buthelezi, J. B. Butt, S. A. Bysiak, D. Caffarri, A. Caliva, E. Calvo Villar, J. M. M. Camacho, R. S. Camacho, P. Camerini, F. D. M. Canedo, A. A. Capon, F. Carnesecchi, R. Caron, J. Castillo Castellanos, A. J. Castro, E. A. R. Casula, F. Catalano, C. Ceballos Sanchez, P. Chakraborty, S. Chandra, W. Chang, S. Chapeland, M. Chartier, S. Chattopadhyay, S. Chattopadhyay, A. Chauvin, C. Cheshkov, B. Cheynis, V. Chibante Barroso, D. D. Chinellato, S. Cho, P. Chochula, T. Chowdhury, P. Christakoglou, C. H. Christensen, P. Christiansen, T. Chujo, C. Cicalo, L. Cifarelli, L. D. Cilladi, F. Cindolo, M. R. Ciupek, G. Clai, J. Cleymans, F. Colamaria, D. Colella, A. Collu, M. Colocci, M. Concas, G. Conesa Balbastre, Z. Conesa del Valle, G. Contin, J. G. Contreras, T. M. Cormier, Y. Corrales Morales, P. Cortese, M. R. Cosentino, F. Costa, S. Costanza, P. Crochet, E. Cuautle, P. Cui, L. Cunqueiro, D. Dabrowski, T. Dahms, A. Dainese, F. P. A. Damas, M. C. Danisch, A. Danu, D. Das, I. Das, P. Das, P. Das, S. Das, A. Dash, S. Dash, S. De, A. De Caro, G. de Cataldo, J. de Cuveland, A. De Falco, D. De Gruttola, N. De Marco, S. De Pasquale, S. Deb, H. F. Degenhardt, K. R. Deja, A. Deloff, S. Delsanto, W. Deng, P. Dhankher, D. Di Bari, A. Di Mauro, R. A. Diaz, T. Dietel, P. Dillenseger, Y. Ding, R. Divià, D. U. Dixit, Ø. Djuvsland, U. Dmitrieva, A. Dobrin, B. Dönigus, O. Dordic, A. K. Dubey, A. Dubla, S. Dudi, M. Dukhishyam, P. Dupieux, R. J. Ehlers, V. N. Eikeland, D. Elia, B. Erazmus, F. Erhardt, A. Erokhin, M. R. Ersdal, B. Espagnon, G. Eulisse, D. Evans, S. Evdokimov, L. Fabbietti, M. Faggin, J. Faivre, F. Fan, A. Fantoni, M. Fasel, P. Fecchio, A. Feliciello, G. Feofilov, A. Fernández Téllez, A. Ferrero, A. Ferretti, A. Festanti, V. J. G. Feuillard, J. Figiel, S. Filchagin, D. Finogeev, F. M. Fionda, G. Fiorenza, F. Flor, A. N. Flores, S. Foertsch, P. Foka, S. Fokin, E. Fragiacomo, U. Frankenfeld, U. Fuchs, C. Furget, A. Furs, M. Fusco Girard, J. J. Gaardhøje, M. Gagliardi, A. M. Gago, A. Gal, C. D. Galvan, P. Ganoti, C. Garabatos, J. R. A. Garcia, E. Garcia-Solis, K. Garg, C. Gargiulo, A. Garibli, K. Garner, P. Gasik, E. F. Gauger, M. B. Gay Ducati, M. Germain, J. Ghosh, P. Ghosh, S. K. Ghosh, M. Giacalone, P. Gianotti, P. Giubellino, P. Giubilato, A. M. C. Glaenzer, P. Glässel, A. Gomez Ramirez, V. Gonzalez, L. H. González-Trueba, S. Gorbunov, L. Görlich, A. Goswami, S. Gotovac, V. Grabski, L. K. Graczykowski, K. L. Graham, L. Greiner, A. Grelli, C. Grigoras, V. Grigoriev, A. Grigoryan, S. Grigoryan, O. S. Groettvik, F. Grosa, J. F. Grosse-Oetringhaus, R. Grosso, R. Guernane, M. Guittiere, K. Gulbrandsen, T. Gunji, A. Gupta, R. Gupta, I. B. Guzman, R. Haake, M. K. Habib, C. Hadjidakis, H. Hamagaki, G. Hamar, M. Hamid, R. Hannigan, M. R. Haque, A. Harlenderova, J. W. Harris, A. Harton, J. A. Hasenbichler, H. Hassan, Q. U. Hassan, D. Hatzifotiadou, P. Hauer, L. B. Havener, S. Hayashi, S. T. Heckel, E. Hellbär, H. Helstrup, A. Herghelegiu, T. Herman, E. G. Hernandez, G. Herrera Corral, F. Herrmann, K. F. Hetland, H. Hillemanns, C. Hills, B. Hippolyte, B. Hohlweger, J. Honermann, D. Horak, A. Hornung, S. Hornung, R. Hosokawa, P. Hristov, C. Huang, C. Hughes, P. Huhn, T. J. Humanic, H. Hushnud, L. A. Husova, N. Hussain, S. A. Hussain, D. Hutter, J. P. Iddon, R. Ilkaev, H. Ilyas, M. Inaba, G. M. Innocenti, M. Ippolitov, A. Isakov, M. S. Islam, M. Ivanov, V. Ivanov, V. Izucheev, B. Jacak, N. Jacazio, P. M. Jacobs, S. Jadlovska, J. Jadlovsky, S. Jaelani, C. Jahnke, M. J. Jakubowska, M. A. Janik, T. Janson, M. Jercic, O. Jevons, M. Jin, F. Jonas, P. G. Jones, J. Jung, M. Jung, A. Jusko, P. Kalinak, A. Kalweit, V. Kaplin, S. Kar, A. Karasu Uysal, D. Karatovic, O. Karavichev, T. Karavicheva, P. Karczmarczyk, E. Karpechev, A. Kazantsev, U. Kebschull, R. Keidel, M. Keil, B. Ketzer, Z. Khabanova, A. M. Khan, S. Khan, A. Khanzadeev, Y. Kharlov, A. Khatun, A. Khuntia, B. Kileng, B. Kim, B. Kim, D. Kim, D. J. Kim, E. J. Kim, H. Kim, J. Kim, J. S. Kim, J. Kim, J. Kim, J. Kim, M. Kim, S. Kim, T. Kim, T. Kim, S. Kirsch, I. Kisel, S. Kiselev, A. Kisiel, J. L. Klay, C. Klein, J. Klein, S. Klein, C. Klein-Bösing, M. Kleiner, A. Kluge, M. L. Knichel, A. G. Knospe, C. Kobdaj, M. K. Köhler, T. Kollegger, A. Kondratyev, N. Kondratyeva, E. Kondratyuk, J. Konig, S. A. Konigstorfer, P. J. Konopka, G. Kornakov, L. Koska, O. Kovalenko, V. Kovalenko, M. Kowalski, I. Králik, A. Kravčáková, L. Kreis, M. Krivda, F. Krizek, K. Krizkova Gajdosova, M. Krüger, E. Kryshen, M. Krzewicki, A. M. Kubera, V. Kučera, C. Kuhn, P. G. Kuijer, L. Kumar, S. Kundu, P. Kurashvili, A. Kurepin, A. B. Kurepin, A. Kuryakin, S. Kushpil, J. Kvapil, M. J. Kweon, J. Y. Kwon, Y. Kwon, S. L. La Pointe, P. La Rocca, Y. S. Lai, M. Lamanna, R. Langoy, K. Lapidus, A. Lardeux, P. Larionov, E. Laudi, R. Lavicka, T. Lazareva, R. Lea, L. Leardini, J. Lee, S. Lee, S. Lehner, J. Lehrbach, R. C. Lemmon, I. León Monzón, E. D. Lesser, M. Lettrich, P. Lévai, X. Li, X. L. Li, J. Lien, R. Lietava, B. Lim, V. Lindenstruth, A. Lindner, C. Lippmann, M. A. Lisa, A. Liu, J. Liu, S. Liu, W. J. Llope, I. M. Lofnes, V. Loginov, C. Loizides, P. Loncar, J. A. Lopez, X. Lopez, E. López Torres, J. R. Luhder, M. Lunardon, G. Luparello, Y. G. Ma, A. Maevskaya, M. Mager, S. M. Mahmood, T. Mahmoud, A. Maire, R. D. Majka, M. Malaev, Q. W. Malik, L. Malinina, D. Mal’Kevich, P. Malzacher, G. Mandaglio, V. Manko, F. Manso, V. Manzari, Y. Mao, M. Marchisone, J. Mareš, G. V. Margagliotti, A. Margotti, A. Marín, C. Markert, M. Marquard, C. D. Martin, N. A. Martin, P. Martinengo, J. L. Martinez, M. I. Martínez, G. Martínez García, S. Masciocchi, M. Masera, A. Masoni, L. Massacrier, E. Masson, A. Mastroserio, A. M. Mathis, O. Matonoha, P. F. T. Matuoka, A. Matyja, C. Mayer, F. Mazzaschi, M. Mazzilli, M. A. Mazzoni, A. F. Mechler, F. Meddi, Y. Melikyan, A. Menchaca-Rocha, C. Mengke, E. Meninno, A. S. Menon, M. Meres, S. Mhlanga, Y. Miake, L. Micheletti, L. C. Migliorin, D. L. Mihaylov, K. Mikhaylov, A. N. Mishra, D. Miśkowiec, A. Modak, N. Mohammadi, A. P. Mohanty, B. Mohanty, M. Mohisin Khan, Z. Moravcova, C. Mordasini, D. A. Moreira De Godoy, L. A. P. Moreno, I. Morozov, A. Morsch, T. Mrnjavac, V. Muccifora, E. Mudnic, D. Mühlheim, S. Muhuri, J. D. Mulligan, A. Mulliri, M. G. Munhoz, R. H. Munzer, H. Murakami, S. Murray, L. Musa, J. Musinsky, C. J. Myers, J. W. Myrcha, B. Naik, R. Nair, B. K. Nandi, R. Nania, E. Nappi, M. U. Naru, A. F. Nassirpour, C. Nattrass, R. Nayak, T. K. Nayak, S. Nazarenko, A. Neagu, R. A. Negrao De Oliveira, L. Nellen, S. V. Nesbo, G. Neskovic, D. Nesterov, L. T. Neumann, B. S. Nielsen, S. Nikolaev, S. Nikulin, V. Nikulin, F. Noferini, P. Nomokonov, J. Norman, N. Novitzky, P. Nowakowski, A. Nyanin, J. Nystrand, M. Ogino, A. Ohlson, J. Oleniacz, A. C. Oliveira Da Silva, M. H. Oliver, C. Oppedisano, A. Ortiz Velasquez, A. Oskarsson, J. Otwinowski, K. Oyama, Y. Pachmayer, V. Pacik, S. Padhan, D. Pagano, G. Paić, J. Pan, S. Panebianco, P. Pareek, J. Park, J. E. Parkkila, S. Parmar, S. P. Pathak, B. Paul, J. Pazzini, H. Pei, T. Peitzmann, X. Peng, L. G. Pereira, H. Pereira Da Costa, D. Peresunko, G. M. Perez, S. Perrin, Y. Pestov, V. Petráček, M. Petrovici, R. P. Pezzi, S. Piano, M. Pikna, P. Pillot, O. Pinazza, L. Pinsky, C. Pinto, S. Pisano, D. Pistone, M. Płoskoń, M. Planinic, F. Pliquett, M. G. Poghosyan, B. Polichtchouk, N. Poljak, A. Pop, S. Porteboeuf-Houssais, V. Pozdniakov, S. K. Prasad, R. Preghenella, F. Prino, C. A. Pruneau, I. Pshenichnov, M. Puccio, J. Putschke, S. Qiu, L. Quaglia, R. E. Quishpe, S. Ragoni, S. Raha, S. Rajput, J. Rak, A. Rakotozafindrabe, L. Ramello, F. Rami, S. A. R. Ramirez, R. Raniwala, S. Raniwala, S. S. Räsänen, R. Rath, V. Ratza, I. Ravasenga, K. F. Read, A. R. Redelbach, K. Redlich, A. Rehman, P. Reichelt, F. Reidt, X. Ren, R. Renfordt, Z. Rescakova, K. Reygers, A. Riabov, V. Riabov, T. Richert, M. Richter, P. Riedler, W. Riegler, F. Riggi, C. Ristea, S. P. Rode, M. Rodríguez Cahuantzi, K. Røed, R. Rogalev, E. Rogochaya, D. Rohr, D. Röhrich, P. F. Rojas, P. S. Rokita, F. Ronchetti, A. Rosano, E. D. Rosas, K. Roslon, A. Rossi, A. Rotondi, A. Roy, P. Roy, O. V. Rueda, R. Rui, B. Rumyantsev, A. Rustamov, E. Ryabinkin, Y. Ryabov, A. Rybicki, H. Rytkonen, O. A. M. Saarimaki, R. Sadek, S. Sadhu, S. Sadovsky, K. Šafařík, S. K. Saha, B. Sahoo, P. Sahoo, R. Sahoo, S. Sahoo, P. K. Sahu, J. Saini, S. Sakai, S. Sambyal, V. Samsonov, D. Sarkar, N. Sarkar, P. Sarma, V. M. Sarti, M. H. P. Sas, E. Scapparone, J. Schambach, H. S. Scheid, C. Schiaua, R. Schicker, A. Schmah, C. Schmidt, H. R. Schmidt, M. O. Schmidt, M. Schmidt, N. V. Schmidt, A. R. Schmier, J. Schukraft, Y. Schutz, K. Schwarz, K. Schweda, G. Scioli, E. Scomparin, J. E. Seger, Y. Sekiguchi, D. Sekihata, I. Selyuzhenkov, S. Senyukov, D. Serebryakov, A. Sevcenco, A. Shabanov, A. Shabetai, R. Shahoyan, W. Shaikh, A. Shangaraev, A. Sharma, A. Sharma, H. Sharma, M. Sharma, N. Sharma, S. Sharma, O. Sheibani, K. Shigaki, M. Shimomura, S. Shirinkin, Q. Shou, Y. Sibiriak, S. Siddhanta, T. Siemiarczuk, D. Silvermyr, G. Simatovic, G. Simonetti, B. Singh, R. Singh, R. Singh, R. Singh, V. K. Singh, V. Singhal, T. Sinha, B. Sitar, M. Sitta, T. B. Skaali, M. Slupecki, N. Smirnov, R. J. M. Snellings, C. Soncco, J. Song, A. Songmoolnak, F. Soramel, S. Sorensen, I. Sputowska, J. Stachel, I. Stan, P. J. Steffanic, E. Stenlund, S. F. Stiefelmaier, D. Stocco, M. M. Storetvedt, L. D. Stritto, A. A. P. Suaide, T. Sugitate, C. Suire, M. Suleymanov, M. Suljic, R. Sultanov, M. Šumbera, V. Sumberia, S. Sumowidagdo, S. Swain, A. Szabo, I. Szarka, U. Tabassam, S. F. Taghavi, G. Taillepied, J. Takahashi, G. J. Tambave, S. Tang, M. Tarhini, M. G. Tarzila, A. Tauro, G. Tejeda Muñoz, A. Telesca, L. Terlizzi, C. Terrevoli, D. Thakur, S. Thakur, D. Thomas, F. Thoresen, R. Tieulent, A. Tikhonov, A. R. Timmins, A. Toia, N. Topilskaya, M. Toppi, F. Torales-Acosta, S. R. Torres, A. Trifiró, S. Tripathy, T. Tripathy, S. Trogolo, G. Trombetta, L. Tropp, V. Trubnikov, W. H. Trzaska, T. P. Trzcinski, B. A. Trzeciak, A. Tumkin, R. Turrisi, T. S. Tveter, K. Ullaland, E. N. Umaka, A. Uras, G. L. Usai, M. Vala, N. Valle, S. Vallero, N. van der Kolk, L. V. R. van Doremalen, M. van Leeuwen, P. Vande Vyvre, D. Varga, Z. Varga, M. Varga-Kofarago, A. Vargas, M. Vasileiou, A. Vasiliev, O. Vázquez Doce, V. Vechernin, E. Vercellin, S. Vergara Limón, L. Vermunt, R. Vernet, R. Vértesi, L. Vickovic, Z. Vilakazi, O. Villalobos Baillie, G. Vino, A. Vinogradov, T. Virgili, V. Vislavicius, A. Vodopyanov, B. Volkel, M. A. Völkl, K. Voloshin, S. A. Voloshin, G. Volpe, B. von Haller, I. Vorobyev, D. Voscek, J. Vrláková, B. Wagner, M. Weber, S. G. Weber, A. Wegrzynek, S. C. Wenzel, J. P. Wessels, J. Wiechula, J. Wikne, G. Wilk, J. Wilkinson, G. A. Willems, E. Willsher, B. Windelband, M. Winn, W. E. Witt, J. R. Wright, Y. Wu, R. Xu, S. Yalcin, Y. Yamaguchi, K. Yamakawa, S. Yang, S. Yano, Z. Yin, H. Yokoyama, I.-K. Yoo, J. H. Yoon, S. Yuan, A. Yuncu, V. Yurchenko, V. Zaccolo, A. Zaman, C. Zampolli, H. J. C. Zanoli, N. Zardoshti, A. Zarochentsev, P. Závada, N. Zaviyalov, H. Zbroszczyk, M. Zhalov, S. Zhang, X. Zhang, Z. Zhang, V. Zherebchevskii, Y. Zhi, D. Zhou, Y. Zhou, Z. Zhou, J. Zhu, Y. Zhu, A. Zichichi, G. Zinovjev & N. Zurlo, Helsinki Institute of Physics, Sub Subatomic Physics (SAP), Afd Subatomic Physics (SAP), Sub Algemeen Physics Education, and Subatomic Physics
Subjects: EXCHANGE-POTENTIAL APPROACH, Strange quark, ALICE Collaboration, Hadron, Nuclear Theory, Strong interaction, hadron collisions, Position and momentum space, hiukkasfysiikka, nucl-ex, 7. Clean energy, 01 natural sciences, VDP::Fysikk: 430, High Energy Physics - Experiment, High Energy Physics - Experiment (hep-ex), Hadron-Hadron scattering (experiments), scattering [hadron], p p scattering, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], scattering [p p], Nuclear Experiment (nucl-ex), Experimental nuclear physics, NUCLEON, Nuclear Experiment, VDP::Physics: 430, Physics, Multidisciplinary, Large Hadron Collider, strong interaction, lattice [space-time], Publisher Correction, PRIRODNE ZNANOSTI. Fizika, BARYON-BARYON SCATTERING, CERN LHC Coll, LHC, ddc:500, Nucleon, Particle Physics - Experiment, discrete [space-time], Quark, Particle physics, CERN Lab, General Science & Technology, FOS: Physical sciences, short-range, Hadron, strong interaction, LHC, 114 Physical sciences, Fysikk: 430 [VDP], Article, hadron scattering, quark, ultrarelativistic proton–proton collisions, LHC, ALICE, 0103 physical sciences, Nuclear Physics - Experiment, General, 010306 general physics, Physics: 430 [VDP], interaction [hadron hadron], hep-ex, 010308 nuclear & particles physics, High Energy Physics::Phenomenology, effect [strong interaction], hadron-hadron interaction, strong interaction: effect, space-time: discrete, space-time: lattice, correlation, NATURAL SCIENCES. Physics, Baryon, Hypernuclei, Neutron Stars, Strangeness, Physics::Accelerator Physics, High Energy Physics::Experiment, hadron, Experimental particle physics
Abstract: One of the key challenges for nuclear physics today is to understand from first principles the effective interaction between hadrons with different quark content. First successes have been achieved using techniques that solve the dynamics of quarks and gluons on discrete space-time lattices1,2. Experimentally, the dynamics of the strong interaction have been studied by scattering hadrons off each other. Such scattering experiments are difficult or impossible for unstable hadrons3–6 and so high-quality measurements exist only for hadrons containing up and down quarks7. Here we demonstrate that measuring correlations in the momentum space between hadron pairs8–12 produced in ultrarelativistic proton–proton collisions at the CERN Large Hadron Collider (LHC) provides a precise method with which to obtain the missing information on the interaction dynamics between any pair of unstable hadrons. Specifically, we discuss the case of the interaction of baryons containing strange quarks (hyperons). We demonstrate how, using precision measurements of proton–omega baryon correlations, the effect of the strong interaction for this hadron–hadron pair can be studied with precision similar to, and compared with, predictions from lattice calculations13,14. The large number of hyperons identified in proton–proton collisions at the LHC, together with accurate modelling15 of the small (approximately one femtometre) inter-particle distance and exact predictions for the correlation functions, enables a detailed determination of the short-range part of the nucleon-hyperon interaction., Correlations in momentum space between hadrons created by ultrarelativistic proton–proton collisions at the CERN Large Hadron Collider provide insights into the strong interaction, particularly the short-range dynamics of hyperons—baryons that contain strange quarks.
Published: 2020
Full Text: View/download PDF

41. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Author: Grzegorz W. Basak, Boris V. Afanasyev, Péter Reményi, Noel Milpied, Paolo Corradini, Madan Jagasia, Olaf Penack, Henrik Sengeloev, Frank Kroschinsky, Zinaida Peric, Ibrahim Yakoub-Agha, Rafael F. Duarte, Dietger Niederwieser, Edward Kanfer, Steffie van der Werf, Fabio Ciceri, Alessandro Rambaldi, Didier Blaise, Patrice Chevallier, Carlos Solano, Hildegard Greinix, Eric Beohou, Luca Castagna, Nicolaus Kröger, Hélène Schoemans, Agnieszka Tomaszewska, Christian Koenecke, Jean Bourhis, Benedetto Bruno, Christof Scheid, Marco Ladetto, Gérard Socié, Tomaszewska, A., Jagasia, M., Beohou, E., van der Werf, S., Blaise, D., Kanfer, E., Milpied, N., Remenyi, P., Ciceri, F., Bourhis, J. H., Chevallier, P., Solano, C., Socie, G., Bruno, B., Rambaldi, A., Castagna, L., Kroger, N., Corradini, P., Afanasyev, B., Ladetto, M., Niederwieser, D., Scheid, C., Sengeloev, H., Kroschinsky, F., Yakoub-Agha, I., Schoemans, H., Koenecke, C., Penack, O., Peric, Z., Greinix, H., Duarte, R. F., and Basak, G. W.
Subjects: Oncology, Male, B-cell malignancy, Transplantation Conditioning, Graft vs Host Disease / etiology, Graft vs Host Disease, Disease, Rituximab / therapeutic use, Single Center, Transplantation Conditioning / methods, rituximab, conditioning, hemic and lymphatic diseases, Neoplasms, graft-versus-host disease, Immunology and Allergy, transplantation, B-cell malignancy, conditioning, rituximab, non-relapse mortality after hematopoietic cell transplantation, graft-versus-host disease, Registries, Young adult, Neoplasms / drug therapy, Original Research, B-Lymphocytes, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Middle Aged, Rituximab, Female, Life Sciences & Biomedicine, medicine.drug, lcsh:Immunologic diseases. Allergy, Adult, medicine.medical_specialty, Lymphoma, B-Cell, Immunology, non-relapse mortality after hematopoietic cell transplantation, transplantation, Disease-Free Survival, Young Adult, Hematopoietic Stem Cell Transplantation / methods, Median follow-up, Internal medicine, medicine, Leukemia, B-Cell, Humans, ddc:610, Aged, Science & Technology, business.industry, Leukemia, B-Cell / drug therapy, medicine.disease, Transplantation, Graft-versus-host disease, B-Lymphocytes / drug effects, business, lcsh:RC581-607, Lymphoma, B-Cell / drug therapy
Abstract: Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001-2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1-77.3) and 43.2 months (range 0.3-179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4° (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study. ispartof: FRONTIERS IN IMMUNOLOGY vol:11 ispartof: location:Switzerland status: published
Published: 2021
Full Text: View/download PDF

42. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Author: Christian Junghanß, Christoph Groth, Nadezda Basara, Sandra Grass, Anja Klein, Inken Hilgendorf, Dietger Niederwieser, Sabine Dressler, Domenico Russo, Matthias Stelljes, Miroslaw Markiewicz, Beate Hauptrock, Daniel Wolff, Christof Scheid, Hélène Labussière-Wallet, Ernst Holler, Wichard Vogel, Peter Dreger, Kerstin Schaefer-Eckart, Heidrun A. Mylius, Goetz Ulrich Grigoleit, Maria Caterina Micò, Joachim Baumgart, Jochen Casper, Fabio Ciceri, Thomas Luft, Dietrich W. Beelen, Anna Paola Iori, Alessandro Rambaldi, Gernot Stuhler, Péter Reményi, Maria Bieniaszewska, Marta Medeot, Tamás Masszi, Nils Rudolf Winkelmann, Udo Holtick, Jacopo Peccatori, Uwe Pichlmeier, Mauricette Michallet, Friedrich Stölzel, Eva Maria Wagner-Drouet, Fabio Benedetti, Stephan Mielke, Johannes Schetelig, Régis Peffault de Latour, Wolfgang Bethge, Georg Nikolaus Franke, Michael Tribanek, Monika Dzierzak-Mietla, Helge Menzel, Gérard Socié, Rudolf Trenschel, Gerald Wulf, Bertram Glass, Christina Grosse-Thie, Mareike Verbeek, Juergen Finke, Francesca Patriarca, Claudia Hemmelmann, Beelen, D. W., Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Remenyi, P., Wagner-Drouet, E. -M., Hauptrock, B., Dreger, P., Luft, T., Bethge, W., Vogel, W., Ciceri, F., Peccatori, J., Stolzel, F., Schetelig, J., Junghanss, C., Grosse-Thie, C., Michallet, M., Labussiere-Wallet, H., Schaefer-Eckart, K., Dressler, S., Grigoleit, G. U., Mielke, S., Scheid, C., Holtick, U., Patriarca, F., Medeot, M., Rambaldi, A., Mico, M. C., Niederwieser, D., Franke, G. -N., Hilgendorf, I., Winkelmann, N. R., Russo, D., Socie, G., Peffault de Latour, R., Holler, E., Wolff, D., Glass, B., Casper, J., Wulf, G., Menzel, H., Basara, N., Bieniaszewska, M., Stuhler, G., Verbeek, M., Grass, S., Iori, A. P., Finke, J., Benedetti, F., Pichlmeier, U., Hemmelmann, C., Tribanek, M., Klein, A., Mylius, H. A., Baumgart, J., Dzierzak-Mietla, M., and Markiewicz, M.
Subjects: Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Population, Medizin, Antineoplastic Agents, Treosulfan, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, education, Busulfan, Preparative Regimen, Aged, education.field_of_study, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Interim analysis, 3. Good health, Fludarabine, Transplantation, Regimen, Leukemia, Myeloid, Acute, 030220 oncology & carcinogenesis, Myelodysplastic Syndromes, Female, business, Vidarabine, 030215 immunology, medicine.drug
Abstract: Background: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. Methods: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18–70 years, had acute myeloid leukaemia in first or consecutive complete haematological remission (blast counts
Published: 2020

43. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author: Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B Dash, Neeraj Gupta, Richard Labotka, S Vincent Rajkumar, Daniel Bar, Alfredo Basso, Dorotea Fantl, Simon He, Neomi Horvath, Cindy Lee, Phillip Rowlings, Kerry Taylor, Tara Cochrane, Fiona Kwok, Sundreswran Ramanathan, Hermine Agis, Niklas Zojer, Alain Kentos, Fritz Offner, Jan Van Droogenbroeck, Ka Lung Wu, Angelo Maiolino, Gracia Martinez, Karla Zanella, Marcelo Capra, Sérgio Araújo, Evzen Gregora, Ludek Pour, Vlastimil Scudla, Ivan Spicka, Niels Abildgaard, Niels Andersen, Bo Amdi Jensen, Carsten Helleberg, Torben Plesner, Morten Salomo, Asta Svirskaite, Richard Delarue, Igor Blau, Aneta Schieferdecker, Veronica Teleanu, Markus Munder, Christoph Röllig, Han-Juergen Salwender, Stephan Fuhrmann, Katja Weisel, Jan Duerig, Matthias Zeis, Stefan Klein, Peter Reimer, Christian Schmidt, Christof Scheid, Karin Mayer, Martin Hoffmann, Markus Sosada, Athanasios Dimopoulos, Sosana Delimpasi, Mary-Christine Kyrtsonis, Achilleas Anagnostopoulos, Zsolt Nagy, Árpád Illés, Miklós Egyed, Zita Borbényi, Gabor Mikala, Najib Dally, Netanel Horowitz, Odit Gutwein, Anatoly Nemets, Iuliana Vaxman, Olga Shvetz, Svetlana Trestman, Rosa Ruchlemer, Arnon Nagler, Tamar Tadmor, Ory Rouvio, Meir Preis, Michele Cavo, Luca De Rosa, Pellegrino Musto, Anna Cafro, Patrizia Tosi, Massimo Offidani, Alessandro Corso, Giuseppe Rossi, Anna Marina Liberati, Alberto Bosi, Kenshi Suzuki, Chiaki Nakaseko, Takayuki Ishikawa, Morio Matsumoto, Hirokazu Nagai, Kazutaka Sunami, Takaaki Chou, Koichi Akashi, Naoki Takezako, Shotaro Hagiwara, Hyeon Seok Eom, Deog-Yeon Jo, Jin Seok Kim, Jae Hoon Lee, Sung Soo Yoon, Dok Hyun Yoon, Kihyun Kim, Mark-David Levin, Edo Vellenga, Monique Minnema, Anders Waage, Einar Haukås, Sebastian Grosicki, Andrzej Pluta, Tadeusz Robak, Herlander Marques, Rui Bergantim, Fernando Campilho, Wee Joo Chng, Yeow Tee Goh, Andrew McDonald, Bernado Rapoport, Miguel Angel Álvarez Rivas, Felipe De Arriba de La Fuente, Yolanda González Montes, Jesus Martin Sanchez, Maria Victoria Mateos, Albert Oriol Rocafiguera, Laura Rosinol, Jesús San Miguel, Jaime Pérez de Oteyza, Cristina Encinas, Adrian Alegre-Amor, Ana López-Guía, Per Axelsson, Kristina Carlson, Olga Stromberg, Markus Hansson, Cecile Hveding Blimark, Rouven Mueller, Chih-Cheng Chen, Ta-Chih Liu, Shang-Yi Huang, Po-Nan Wang, Thanyaphong Na Nakorn, Kannadit Prayongratana, Ali Unal, Hakan Goker, Mehmet Sonmez, Sybiryna Korenkova, Aristeidis Chaidos, Heather Oakervee, Hamdi Sati, Reuben Benjamin, Ashutosh Wechalekar, Mamta Garg, Karthik Ramasamy, Gordon Cook, Andrew Chantry, Matthew Jenner, Francis Buadi, Robert Berryman, Murali Janakiram, Takeda Pharmaceutical Company, Dimopoulos MA1, Gay F2, Schjesvold F3, Beksac M4, Hajek R5, Weisel KC6, Goldschmidt H7, Maisnar V8, Moreau P9, Min CK10, Pluta A11, Chng WJ12, Kaiser M13, Zweegman S14, Mateos MV15, Spencer A16, Iida S17, Morgan G18, Suryanarayan K19, Teng Z19, Skacel T19, Palumbo A20, Dash AB19, Gupta N19, Labotka R19, Rajkumar SV21, TOURMALINE-MM3 study group. Bar D, Basso A, Fantl D, He S, Horvath N, Lee C, Rowlings P, Taylor K, Spencer A, Cochrane T, Kwok F, Ramanathan S, Agis H, Zojer N, Kentos A, Offner F, Van Droogenbroeck J, Wu KL, Maiolino A, Martinez G, Zanella K, Capra M, Araújo S, Gregora E, Hajek R, Maisnar V, Pour L, Scudla V, Spicka I, Abildgaard N, Andersen N, Jensen BA, Helleberg C, Plesner T, Salomo M, Svirskaite A, Delarue R, Moreau P, Blau I, Goldschmidt H, Schieferdecker A, Teleanu V, Munder M, Röllig C, Salwender HJ, Fuhrmann S, Weisel K, Duerig J, Zeis M, Klein S, Reimer P, Schmidt C, Scheid C, Mayer K, Hoffmann M, Sosada M, Dimopoulos A, Delimpasi S, Kyrtsonis MC, Anagnostopoulos A, Nagy Z, Illés Á, Egyed M, Borbényi Z, Mikala G, Dally N, Horowitz N, Gutwein O, Nemets A, Vaxman I, Shvetz O, Trestman S, Ruchlemer R, Nagler A, Tadmor T, Rouvio O, Preis M, Gay F, Cavo M, De Rosa L, Musto P, Cafro A, Tosi P, Offidani M, Corso A, Rossi G, Liberati AM, Bosi A, Suzuki K, Iida S, Nakaseko C, Ishikawa T, Matsumoto M, Nagai H, Sunami K, Chou T, Akashi K, Takezako N, Hagiwara S, Eom HS, Jo DY, Kim JS, Lee JH, Min CK, Yoon SS, Yoon DH, Kim K, Zweegman S, Levin MD, Vellenga E, Minnema M, Schjesvold F, Waage A, Haukås E, Grosicki S, Pluta A, Robak T, Marques H, Bergantim R, Campilho F, Chng WJ, Goh YT, McDonald A, Rapoport B, Álvarez Rivas MA, De Arriba de La Fuente F, González Montes Y, Martin Sanchez J, Mateos MV, Oriol Rocafiguera A, Rosinol L, San Miguel J, Pérez de Oteyza J, Encinas C, Alegre-Amor A, López-Guía A, Axelsson P, Carlson K, Stromberg O, Hansson M, Hveding Blimark C, Mueller R, Chen CC, Liu TC, Huang SY, Wang PN, Na Nakorn T, Prayongratana K, Beksac M, Unal A, Goker H, Sonmez M, Korenkova S, Chaidos A, Oakervee H, Sati H, Benjamin R, Wechalekar A, Garg M, Kaiser M, Ramasamy K, Cook G, Chantry A, Jenner M, Buadi F, Berryman R, Janakiram M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, and Hematology
Subjects: Male, Time Factors, DIAGNOSED MULTIPLE-MYELOMA, Clinical Trial, Phase III, Administration, Oral, 030204 cardiovascular system & hematology, Ixazomib, chemistry.chemical_compound, 0302 clinical medicine, Autologous stem-cell transplantation, Maintenance therapy, Clinical endpoint, 030212 general & internal medicine, Non-U.S. Gov't, Boron Compounds/administration & dosage, IMPROVES SURVIVAL, INDUCTION, Research Support, Non-U.S. Gov't, General Medicine, CHEMOTHERAPY, Middle Aged, Clinical Trial, DEXAMETHASONE, Antineoplastic Agents/administration & dosage, Multicenter Study, Treatment Outcome, Administration, Randomized Controlled Trial, Disease Progression, Female, Multiple Myeloma, Autologous, Boron Compounds, Oral, medicine.medical_specialty, Glycine, Multiple Myeloma/drug therapy, BORTEZOMIB, Antineoplastic Agents, Placebo, Research Support, Transplantation, Autologous, 03 medical and health sciences, Phase III, Double-Blind Method, Internal medicine, medicine, Journal Article, Humans, THALIDOMIDE, Transplantation, business.industry, Clinical trial, LENALIDOMIDE MAINTENANCE, Regimen, chemistry, autologous stem cell transplantation, multiple myeloma, Ixazomib, business, HIGH-DOSE THERAPY, Glycine/administration & dosage, Stem Cell Transplantation
Abstract: [Background]: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. [Methods]: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m²) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1–4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. [Findings]: Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3–35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7–33·8] vs 21·3 months [18·0–24·7]; hazard ratio 0·72, 95% CI 0·58–0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. [Interpretation]: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma, This study was sponsored by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.
Published: 2019
Full Text: View/download PDF

44. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT

Author: Marie Robin, Uwe Platzbecker, Arnold Ganser, Dietrich W. Beelen, Jakob Passweg, Junfeng Wang, Patrick Hayden, Johan Maertens, Christoph Scheid, Amandine Charbonnier, Liesbeth C. de Wreede, Fabio Ciceri, Jürgen Finke, Martin Bornhäuser, Nicolaus Kroeger, Hélène Labussière-Wallet, Patrice Chevallier, Noel Milpied, Linda Koster, Didier Blaise, Francesca Bonifazi, Jan J. Cornelissen, Ibrahim Yakoub-Agha, Robin, M., Wang, J., Koster, L., Beelen, D. W., Bornhauser, M., Kroeger, N., Platzbecker, U., Finke, J., Ganser, A., Blaise, D., Ciceri, F., Maertens, J., Labussiere-Wallet, H., Chevallier, P., Passweg, J. R., Cornelissen, J. J., Milpied, N., Charbonnier, A., Bonifazi, F., de Wreede, L. C., Hayden, P., Scheid, C., and Yakoub-Agha, I.
Subjects: Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunology, Medizin, Cancer, Cell Biology, Hematology, Hematopoietic stem cell transplantation, medicine.disease, Biochemistry, Chemotherapy regimen, Lymphoma, Myeloid Neoplasm, Transplantation, Leukemia, Breast cancer, hemic and lymphatic diseases, Internal medicine, medicine, business
Abstract: Patients with t-MN have a poor prognosis with median overall survival < 1 year due to high risk features of the disease and refractoriness to chemotherapy. HSCT represents the only curative treatment. Outcome after HSCT has progressively improved over time with a last EBMT study showing a 2-year OS at 44% in patients with secondary leukemia (79% post MPN or MDS) (BBMT 2018: 1406). Previous large studies showed survival < 30% in patients transplanted for t-MN (Blood. 2010:1850; Haematologica 2009:542). We recently reported in patients transplanted for a leukemia arising from MDS, MPN and CMML that the primary disease impacts the outcome, particularly patients with a previous MPN had the worst outcome (BJH, 2019: 725). We report here outcome of patients who received HSCT for a t-MN (excluding post MDS, MPN and CMML) with the hypothesis that the primary cancer impacts the outcome. From EBMT registry, patients with MDS or AML occurring after a primary cancer who received a HSCT between 01/06 and 12/16 were included. OS and RFS were analyzed using Kaplan Meier curves and log-rank test, relapse and NRM were analyzed as competing risks with cumulative incidence curves and Gray's test. 2334 patients were identified. Primary cancers were CLL in 102, non-Hodgkin lymphoma (NHL) in 668, Hodgkin lymphoma (HL) in 235, plasma cell disease (PCD) in 111, breast cancer in 643 and other solid tumor (ST) in 575. 981 patients had MDS and 1353 had AML at time of transplantation. Performance status by Karnofsky score was 90 or higher in 1376 (59%) patients. 722 (31%) patients were transplanted from HLA matched sibling donor (SIB) and 843 (36%) received a myelo-ablative conditioning regimen (MAC). 1307 patients were in remission at time of transplantation: 29% of MDS and 76% of AML patients. Three-year OS and RFS were 34 and 32% respectively. OS was significantly better in patients with AML in CR (43%) than not in CR (21%). OS and DFS were impacted by the primary cancer: post NHL (30 and 27%), post HL (29 and 28%), post ST (34% for both), post breast cancer (41 and 37%), post CLL (34 and 31%) and post PCD (32 and 25%) (p The multiple variables models includes age, regimen intensity, donor type, Karnofsky score, t-MN category (AML in CR, AML not in CR, MDS) and the primary type of cancer. Patients with HL (HR: 1.36, p=0.005) or NHL (HR: 1.31, p=0.001) had a higher adjusted risk for OS than patients with other primary diseases. Other risk factors for OS were t-MN type (AML not in CR, HR: 1.45, AML in CR, HR: 0.76, MDS = reference, p Conclusion: A quarter to one third of patients with t-MN can be cured by HSCT which was influenced by type of t-MN and performance status. The type of primary cancer influenced also the outcome with lower mortality, especially NRM in patients with previous solid tumor or PCD as compared to patients with lymphoma. Disclosures Robin: Novartis Neovii: Research Funding. Beelen:Medac GmbH Wedel Germany: Consultancy, Honoraria. Kroeger:DKMS: Research Funding; Neovii: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Riemser: Research Funding; JAZZ: Honoraria; Sanofi-Aventis: Honoraria; Novartis: Honoraria, Research Funding; Medac: Honoraria. Platzbecker:Celgene: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria. Finke:Riemser: Honoraria, Other: research support, Speakers Bureau; Neovii: Honoraria, Other: research support, Speakers Bureau; Medac: Honoraria, Other: research support, Speakers Bureau. Blaise:Pierre Fabre medicaments: Honoraria; Molmed: Consultancy, Honoraria; Sanofi: Honoraria; Jazz Pharmaceuticals: Honoraria. Chevallier:Daiichi Sankyo: Honoraria; Incyte: Consultancy, Honoraria; Jazz Pharmaceuticals: Honoraria.
Published: 2019
Full Text: View/download PDF

45. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

Author: K. Douglas, Richard Noppeney, Anne Parker, R Taylor, Nina Worel, Tamás Masszi, Roberto M. Lemoli, Christoph Scheid, Gabor Mikala, S W Bokhari, Patrick Hayden, Antonio Pagliuca, Joseph P. Uberti, J Treisman, M Maris, Amin Rahemtulla, Graham P. Cook, Alessandra D'Addio, K Rao, Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli R.M., Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, and J Treisman.
Subjects: Male, Benzylamines, mobilizers, dialysi, medicine.medical_treatment, Medizin, Myeloma, Cyclams, chemotherapy, autologous transplantation, Heterocyclic Compounds, Granulocyte Colony-Stimulating Factor, collection, Medicine, Renal Insufficiency, Kidney transplantation, Multiple myeloma, Hematology, Middle Aged, Hematopoietic Stem Cell Mobilization, Blood Component Removal, Female, Multiple Myeloma, medicine.drug, Adult, medicine.medical_specialty, blood stem-cells, Anti-HIV Agents, lenalidomide, g-csf, lymphoma, Transplantation, Autologous, Renal Dialysis, autologous HSC transplant, Humans, Transplantation, Homologous, Autologous transplantation, Dialysis, Aged, Lenalidomide, Peripheral Blood Stem Cell Transplantation, Transplantation, therapy, Dose-Response Relationship, Drug, business.industry, Plerixafor, medicine.disease, Kidney Transplantation, Surgery, kidney failure, Apheresis, multiple-myeloma, dialysis, business
Abstract: We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34+ cell dose of 4.6 x 10(6) per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24 mg/kg/day, resulting in a CD34+ cell dose of 2.12 x 10(6)/kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group. Bone Marrow Transplantation (2012) 47, 18-23; doi: 10.1038/bmt.2011.9; published online 28 February 2011
Published: 2012

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

45 results on '"Scheid C"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources